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Depression, also known as major depressive disorder, major depression, unipolar depression 
or clinical depression, is one of the most serious disorders in today’s society. With a lifetime 
prevalence of approximately 20% in the United States (Kessler et al., 2005) and by affecting 
not only the individuals but also their families and surrounding social environments, this    
illness cannot be overestimated.  
Depression is currently among the three leading contributors to the global disease burden 
(Collins et al., 2011) and is associated with high levels of morbidity and mortality (Evans et 
al., 2005). As the most prominent risk factor for suicide, and therefore a leading cause of 
death worldwide (Saveanu and Nemeroff, 2012), depression results each year in the loss of 
about 850 000 lives worldwide (Chung et al., 2011). Furthermore, affected patients are at 
higher risk of developing physical health problems, namely diabetes (Knol et al., 2006) or 
coronary artery disease (Baune et al., 2012) and additionally the prognosis of other medical 
conditions is aggravated when a comorbidity with depression is present (Evans et al., 2005).  
A major problem in the diagnosis and treatment of depression is that the mechanisms of the 
disease are not yet fully understood and therefore the possibilities of curing affected patients 
are still unsatisfactory (Pollak et al., 2010). The range of available therapeutic options for  
affected persons is narrow and standard pharmacological treatment plans are only successful 
in 30% - 40% (Li et al., 2012a) and often result in serious side effects (Gibiino and Serretti, 
2012). 
Despite the alarming numbers in terms of prevalence and possible negative consequences, 
research is still a long way from understanding the underlying mechanisms that may lead to 
this heterogeneous disease. Further research is required to investigate the interaction between 
different pathological processes as well as provide new etiological hypotheses. 
The aim of this thesis is to contribute to the growing knowledge of depression by providing a 
comprehensive characterization of a mouse model that may be utilized as an animal model of 
depression. It is essential to continue research for the comprehension of this complex disorder 
in order to develop new approaches that may help to overcome it and it is undeniable that   
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 Introduction 
animal models must have a crucial contribution in present and future research. Therefore, an 
entirely new mouse strain is brought into focus that will participate to better understand     
depression and its contributing factors. New insights obtained by this means could possibly 



















2.1 Depression in humans 
 
2.1.1 Etiology 
Looking at the etiology of depression, meta-analyses revealed that approximately 30% - 40% 
of disease developing risk is heritable (Sullivan et al., 2000), with women suffering twice as 
often as men (Weissman et al., 1996). Several specific genes are thought to be associated with 
depression. Probably the most extensively studied gene is the promoter region of the serotonin 
transporter gene (5-HTTLPR), although many studies demonstrated the involvement of vari-
ous other genes in humans (for review see Saveanu and Nemeroff, 2012). 
Despite genetic factors, environmental challenges play a crucial role in the risk of developing 
a depression. A number of studies have shown that onset of depression is undoubtedly influ-
enced by stressful life events during childhood, such as sexual or physical abuse as well as 
neglect (e.g. Zlotnick et al., 1995, Mullen et al., 1996). Caspi et al. (2003) could even reveal a 
significant association between 5-HTTLPR, stress and depression. Depending on the geno-




One of the major problems that occurs when dealing with depression is the lack of objective 
diagnostic tests. Consequently, diagnoses are based on subjective judgement of physicians or 
investigators with the focus on symptoms, signs and course of illness.  
In order to provide a coherent standard for the classification of this disease, the criteria for 
major depressive episode - contained in the Diagnostic and Statistical Manual of Mental    
Disorders, 4
th
 edition, text revision (DSM-IV-TR) - are used (American Psychiatric 
Association., 2000). In this manual typical symptoms of depression are conceived (Table 1).  
 

















Table 1: DSM-IV-TR criteria for major depressive disorder  
   - mod. from Nestler et al. (2010) 
 
2.1.3 Pathophysiology 
Although the pathophysiology of depression is poorly understood, there are several         
mechanisms thought to be associated with the pathogenesis of this disorder.  
Different non-physiological observations have been reported in depressed patients, but often it 
cannot be clearly determined if the changes are indeed causing the outbreak, if they are one of 
many contributing factors or if they are secondary findings. The observations reported with 
regard to depression include a reduced activity in neurotransmission, a dysregulation of the 
hypothalamo-pituitary-adrenal (HPA) axis, a reduction in brain neurotrophins (for review see 
DSM criteria for major depressive episode 
 
A. At least five of the following symptoms are present simultaneously for at 
least 2 weeks (symptom 1 or 2 is necessary): 
 
1. Depressed or irritable mood 
2. Markedly diminished interest or pleasure in all, or almost all,  
    daily activities 
3. Substantial weight loss or weight gain 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or inappropriate guilt nearly every day 
8. Diminished ability to think or concentrate nearly every day 
9. Recurrent thoughts of death or suicide 
 
B. It cannot be established that an organic factor is the cause and the disturb-
ance is not a normal reaction to the death of a loved one (abstracted from 
DSM-IV-TR (American Psychiatric Association., 2000)) 
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Palazidou, 2012) as well as elevated levels of pro-inflammatory cytokines (e.g. Pollak and 
Yirmiya, 2002, Lotrich et al., 2007). These observed changes are often accompanied with 
structural abnormalities within certain brain areas, such as a reduction in the volume of the 
hippocampus or a decreased neuronal density in the prefrontal cortex (for review see Femenia 
et al., 2012). 
The complexity of depression suggests that alterations of several different systems play a role 
in its pathogenesis.  
 
2.1.3.1 The role of the immune system 
One of the hypotheses that have been proposed is the “inflammatory”- or “cytokine           
hypothesis”. The activation of the immune system is thought to provoke a psycho-
neuroimmunological dysfunction (Zunszain et al., 2012) that leads to depressive symptoms.  
Increased levels of pro-inflammatory cytokines, chemokines, acute phase proteins and cellular 
adhesion molecules could be found in depressed patients (Raison et al., 2006). Furthermore, it 
could be observed that patients undergoing an infection, chronic disease or immunotherapy 
frequently develop symptoms of depression independently of the sickness that is present 
(Dantzer et al., 2008).   
In a study from Capuron and Miller (2004), the initiation of interferon-alpha (IFN-α) immu-
notherapy was followed by symptoms of influenza-like sickness and later 30% - 50% of the 
patients suffered from major depression and more than 80% of the patients revealed depres-
sive symptomology, providing a remarkable evidence that pro-inflammatory cytokines are 
linked to the subsequent depressive disorder. Similar studies have been published by other 
authors (e.g. Pollak and Yirmiya, 2002, Lotrich et al., 2007). Further support for the role of 
cytokines in developing depression is provided by the finding from Musselmann et al. (2001), 
who observed that IFN-α-induced depression in patients undergoing immunotherapy is re-
sponsive to treatment with standard antidepressants. 
One proposed pathway that may lead to depression is the ability of pro-inflammatory cyto-
kines, such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), to directly 
activate the enzyme indoleamine 2,3 – dioxygenase (IDO) (Dantzer et al., 2008). The        
extrahepatic enzyme IDO can be found in immune cells, including macrophages and dendritic 
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cells, where it degrades the essential amino acid tryptophan into kynurenine (Wirleitner et al., 
2003). Under physiological conditions tryptophan degradation to kynurenine is negligible, but 
the enzyme is highly inducible by pro-inflammatory cytokines and consequently causes a re-
duced bioavailability of tryptophan (Dantzer et al., 2008).  Kynurenine is a precursor of the 
bioactive metabolite quinolinic acid (QUIN), which is an N-methyl-D-aspartate (NMDA) 
receptor agonist, potentially neurotoxic and therefore assumed to contribute to depression 
(Muller and Schwarz, 2007). But simultaneously kynurenine is also a precursor of kynurenic 
acid (KYNA) that is generally considered to be neuroprotective because of its characteristic as 
an NMDA receptor antagonist (Moroni, 1999).  
It has been proposed that reduced peripheral availability of tryptophan (the precursor of sero-
tonin) leads to a decreased synthesis of serotonin in the brain and that this constriction as well 
as imbalances between QUIN and KYNA may result in depression and neurodegeneration 
(Capuron and Miller, 2004, Dantzer et al., 2008, O'Connor et al., 2009). 
 







Quinolenic acid    
(QUIN) 
Kynurenic acid    






IDO indoleamine 2,3–dioxygenase 
KAT  kynurenine aminotransferase 
KMO  kynurenine 3–monooxygenase 
KYNU  kynureninase 
TPH  tryptophan hydroxylase 
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Another way cytokines contribute to the development of depression is their ability to activate 
the serotonin transporter and cause a reduction of available extracellular serotonin. It has been 
shown that cytokines such as interleukin-1-beta (IL-1ß) and tumor necrosis factor-alpha 
(TNF-α) activate the mitogen activated proteinkinase p38 (MAPK p38) increasing serotonin 
transport activity of the serotonin transporter (Zhu et al., 2006). 
 
 
Figure 2: Simplified effect of cytokines on the serotonin transporter  
               (mod. from text passages - Zhu et al. (2006))  
 
 
2.1.3.2 The role of the HPA axis and stress  
The disturbance of the hypothalamic pituitary adrenal (HPA) axis is a main characteristic   
feature of depression (Palazidou, 2012) and could be demonstrated by Holsboer et al. (1982). 
In the study, depressed patients had elevated levels of plasma cortisol which could not be      
suppressed by administration of dexamethasone. Various research has been found to link the 
HPA axis to the development of depression (for review see Zunszain et al., 2012), but it is 
still unknown why depressed patients often show these disturbances of the HPA axis 
(Carvalho and Pariante, 2008). 
It is known that cytokines alter the negative feedback mechanism enhancing the release of the 
corticotropin-releasing hormone (CRH) from the paraventricular nucleus of the hypothalamus 
(Pace et al., 2007), leading to elevated plasma levels of cortisol and increasing levels of the 
adrenocorticotropic hormone (ACTH).  
Stress is an influencing factor on the HPA axis and thought to be a predominant course in 





Cytokines MAPK p38   SERT 
MAPK p38       mitogen activated    
proteinkinase p38 
SERT  serotonin     
transporter               
  










Figure 3: Simplified effect of cytokines on the HPA axis                                                    
(mod. from text passages - Pace et al. (2007))  
 
2.1.3.3 The role of aging 
The aging progress is accompanied by various changes in the body: The organism is shifted 
into a pro-inflammatory state that is characterized by an increased activity of the innate     
immune system, a disproportional central nervous system (CNS) response when challenged 
by immune stimuli and a disruption of the periphery-CNS immune communication (for 
review see Alexopoulos and Morimoto, 2011). An elevated amount of cytokines, especially 
interleukin-6 (IL-6) (Bremmer et al., 2008) and interleukin-1-beta (IL-1ß) (Thomas et al., 
2005), has been found to be linked to depressive symptoms in elderly. These processes lead to 
elevated numbers of activated microglia cells and an enhanced production of pro-
inflammatory cytokines in the brain combined with decreased levels of anti-inflammatory 
cytokines (Sparkman and Johnson, 2008). The activation of microglia then leads to disturb-
ances in the cell’s metabolic mechanisms and results in neuron loss, insufficient clearance of 
neurotoxic molecules and reduction of neurogenesis (Carpentier and Palmer, 2009).  
Based on these observations, Alexopoulos and Morimoto (2011) suggest that aging-related 
processes may contribute to the etiology of depressive syndromes in older adults. The authors 
assume that the pro-inflammatory state is likely to induce changes in the emotional and cogni-









CRH  corticotropin-releasing hormone 
ACTH  adrenocorticotropic hormone 
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2.1.3.4 Multiple neurotransmitters involved in depression 
Although research has shown that various neurotransmitter systems are pathologically       
involved in the development of depression, no single neurotransmitter system seems to be 
solely responsible. Much research demonstrates that alterations in the metabolism of various 
neurotransmitters such as norepinephrine, dopamine and glutamate are linked to the patho-
physiology of depression (for review see Saveanu and Nemeroff, 2012). 
With this knowledge, this thesis will focus on the serotonergic system, because studying all 
possible changes would go beyond the scope of the thesis.  
 
2.1.3.5 Serotonin alterations in depression  
Serotonin (= 5-hydroxytryptamine (5-HT)) is known to be a neurotransmitter of the central 
and peripheral nervous system and modulates many different physiological processes such as 
sleep, mood and appetite (e.g. Hipolide et al., 2005, Serretti et al., 2006). In the brain, seroto-
nin is released into the synaptic cleft and is then actively transported back into the presynaptic 
neurons by the serotonin transporter (SERT) (Fjorback et al., 2009). 
Several alterations of the serotonergic system have been postulated to be associated with   
depression: Evidence of the involvement of the serotonin circuit includes a reduced activity of 
serotonergic neurons in depressed patients who have made a suicide attempt compared to pa-
tients who have not made a suicide attempt (Mann et al., 1996). Further support comes from 
post-mortem and positron emission tomography (PET) imaging studies that showed a signifi-
cant reduction in the number of serotonin transporter binding sites in certain brain areas of 
depressed patients (Drevets et al., 1999).  Furthermore, humans that possess the ”s” allele of 
the promoter region of the serotonin transporter gene, and hence a lower transcriptional effi-
ciency, are more vulnerable to depressogenic effects caused by stressful life events than indi-
viduals with the ”l” allele (Caspi et al., 2003). 
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2.1.4 Serotonin receptors and the serotonin agonist DOI 
Serotonin targets seven different classes of serotonin receptors (5-HT1 – 5-HT7) that are     
divided into 14 subfamilies (Nichols + Nichols 2008). The 5-HT2 receptor class contains three 
subtypes that are G-protein-coupled and classified as 5-HT2A, 5-HT2B and 5-HT2C 
(Halberstadt et al., 2009).  
In order to evoke serotonin mimetic effects in the mice described in this thesis, and to investi-
gate potential alterations in the reaction to this substance due to disturbances of the            
serotonergic system, the serotonin agonist DOI ((±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-
aminopropane) was used. DOI is relatively selective for activating all HT2 receptor subtypes 
and has a high affinity for these receptors (Canal and Morgan, 2012).  
 
2.1.5 Serotonin transporter 
The serotonin promoter region of the serotonin transporter gene (SLC6A4), in humans located 
on 17q11.2, is modified by sequence elements within the proximal 5´ regulatory region, 
termed the serotonin transporter gene linked polymorphic region (5-HTTLPR) (Caspi et al., 
2003). 
The serotonin transporter is exclusively located on the presynaptic cell membrane of sero-
tonergic neurons in various brain areas, such as in the raphe complex, neocortical regions, 
amygdala, CA3 region of the hippocampus and hypothalamus (Benninghoff et al., 2012). 
Although the exact functions of the transporter still need to be investigated, the current state 
of scientific research assumes that the transporter contains 12 hydrophobic transmembrane 
domains and binds sodium, chloride and serotonin simultaneously. By performing this proce-
dure the serotonin transporter is a major regulator of the serotonin availability in the synaptic 
cleft and therefore highly influences the downstream signalling via the pre-and postsynaptic 
receptors (Fox et al., 2007).   
Inhibiting the uptake of serotonin leads to a relative increase of serotonin in the synaptic cleft 
and enhances the serotonin neurotransmission which might be diminished in a depressed   
patient (Auerbach and Hjorth, 1995). 
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2.1.6 Glycoprotein M6B 
In this thesis mice lacking the glycoprotein M6B (Gpm6b) are described.  
M6B belongs to a proteolipid protein family and is expressed in neurons as well as in        
oligodendrocytes in most brain regions (Werner et al., 2001). Besides that, basal levels of 
M6B mRNA are also detectable in many non-neuronal tissues, such as testis, lung, heart and 
spleen (Werner et al., 2001, Isensee et al., 2008).  
In humans, the gene for M6B is located at chromosome Xp22.2 (Sebastiani et al., 2008) and 
an increased expression in females could be demonstrated (Isensee et al., 2008). Interestingly, 
M6B has been shown to be downregulated in suicide completers which leads to the assump-
tion that elevated levels of this gene may be protective against suicide (Fiori et al., 2011).   
M6B is a four-transmembrane protein that interacts with the N-terminal domain of the seroto-
nin transporter in the brain. It is involved in cellular housekeeping functions and mediates a 
decrease in serotonin transporter surface expression, even though it is still uncertain whether 
M6B facilitates endocytoses or inhibits exocytosis of the serotonin transporter (Fjorback et 
al., 2009). 
Fjorback et al. (2009) demonstrated that in HEK-MSR-293 cells transfected with the          
serotonin transporter and either M6B or pcDNA3 (control) the membrane-bound level of the 
serotonin transporter was reduced about 50% when co-expressed with M6B compared to the 
cells co-transfected with pcDNA3. The same study demonstrated that co-expression of the 
serotonin transporter with M6B in HEK-MSR-293 cells also mediated a dose-dependent re-
duction in the serotonin uptake when compared to cells transfected with pcDNA3.    
According to Werner et al. (2001), M6B is additionally involved in myelination and it is    
upregulated in the brain during terminal neuronal differentiation and myelination.  
The glycoprotein M6A, which is expressed only in neurons and has a 55% sequence identity 
with M6B (Fjorback et al., 2009), is known to interact with the µ-opioid receptor and was 
demonstrated to facilitate the endocytosis and recycling of this receptor (Wu et al., 2007) 
which supports the hypothesis that M6B is also involved in alterations of transporter         
expression (Fjorback et al., 2009). 
- 12 - 
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2.2 Depression in animals 
 
2.2.1 Animal models of depression 
 
2.2.1.1 Requirements  
In order to investigate characteristics and treatment of various diseases, use of animal models 
are inevitable whenever the study on humans is unethical or impractical.  
Animal models are evaluated against different criteria that they should fulfil ideally. Face 
validity, construct validity and pharmacological validity are key requirements a model should 
meet to serve as a model for neuropsychiatric syndromes. 
The “face validity” of a model of depression describes the symptomatic homology to       
symptoms as they are found in depressed humans. Many models are able to meet this        
requirement although the described phenotypes are generally transient and do not occur     
simultaneously (Krishnan and Nestler, 2010). According to Nestler and Hyman (2010), it 
cannot be expected that animal models mirror the full extent of a human disorder like depres-
sion as it is defined in DSM-IV, as the diagnosis in human patients is often built on judgement 
of investigators and reviewers and therefore often arbitrary and hazy. Furthermore, the      
authors remark that specific symptoms observed in animals may not necessarily have a     
simple, straightforward correspondence to symptoms found in depressed humans. Some 
symptoms of humans like suicidal thoughts or feelings of guilt are simply not possible to   
investigate in  animals.  
“Construct validity” is a model’s ability to replicate the etiological background of certain 
phenotypes by using paradigms of genetic and/or environmental manipulations (Krishnan and 
Nestler, 2010). Meeting these criteria constitutes a great challenge, as the factors that are    
implicated in human depression are themselves not entirely understood (Krishnan and Nestler, 
2010). For example, different human patients likely have different genetic pathways that   
contribute to their depressed symptoms (Nestler and Hyman, 2010). 
The term “pharmacological” or “predictive validity” refers to the ability of currently available 
antidepressant modalities to reverse the depressive-like phenotype of the model (Krishnan and 
Nestler, 2010). Many models already meet this criteria, but considering that generally     
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available pharmacological drugs are monoamine modulators and only a minority of human 
patients gain remission after first-line therapies with that type of drug (Li et al., 2012a), it 
should not be mandatory for a model to fulfil the requirement for pharmacological validity in 
order to be considered an applicable animal model.  
 
2.2.1.2 Examples for animal models of depression 
Various studies could describe depressive-like symptoms in different animal species,        
suggesting that this disease is particularly suitable to be modelled in animals. Many of the 
following examples describe depressive-like behavior caused by separation of the animal 
from the offspring, mother or partner. These observations in animals provide valuable evi-
dence that various species are able to exhibit symptoms that resemble depression in humans. 
Monkeys especially aroused researcher’s attention in the early studies of depression on animal 
models. Harlow and Suomi (2012b) observed that infant rhesus monkeys displayed features 
of depression after separation from their mother. The behavioral changes included a reduction 
in play, appetite and social interaction and an increase of crying and sleep disturbances. The 
changes lasted until reunion with the mother. Similar findings were published previously by 
Hinde et al. (2008) as well as Jensen and Tolman (2008). Other species of monkeys revealed 
comparable symptoms when separated from the mother or partner (for review see Zhu et al., 
2007). 
But not only monkeys (a species that is closer related to humans than any other animal)      
exhibited depressive-like symptoms. In other studies authors describe dog puppies that 
demonstrated typical symptoms of depression after separation from the investigator (Zhu et 
al., 2006) or a bitch that was “classically depressed” after the loss of her litter (Graham et al., 
1994).  
Well socialized dogs have been shown to initially develop both agitation as well as acute  
distress and subsequently retardation, weight loss and finally death when they were isolated 
for an extended duration (Scott et al., 1973). 
A depressive-like phenotype was also described in birds. Species that were characterized in-
clude geese, jack{McKinney, 1969 #10}daw birds or the African parrot (for review see Zhu et 
al., 2007). 
e s es eciall  ar se  researcher’s attention in the early studies of depression on animal 
els. It could be observed that infant rhesus monkeys displayed features of depression after 
separation from their mother (Harlow and Suomi, 1974). The behavioral changes included a 
reduction in play, appetite a d social interaction and an increase of crying and sleep disturb-
ances. The changes lasted until reunion with the mother. Similar findings were published pre-
viously Jensen and Tolman (1962). Other species of monkeys revealed comparable symptoms 
when separated fro  the mother or partner (for review see McKinney and Bunney, 1969). 
But not only monkeys (a species that is closer related to humans than any other animal)      
exhibited depressive-like symptoms. In other studies authors describe dog puppies that de on-
strated typical symptoms of depression after separation from the investigator (Senay et al., 
1966) or a bitch that was “classically depressed” after the loss of her litter (Saul et al., 1962).  
Well socialized dogs have been shown to initially develop both agitation as well as acute dis-
tress and subsequently retardation, weight loss and finally death when they were isolated for an 
extended duration (Scott et al., 1973). 
A depressive-like phenotype was also described in birds. Species that were characterized in-
clude geese, jackdaw birds or the African parrot (for review see McKinney and Bunney, 1969). 
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More recent studies focus not only on the symptoms of depression in different species but 
also ask the question how a particular phenotype might be used to serve as a model for human 
depression. Fureix et al. (2004) investigated the influence of chronic stress on domestic horses 
and Hymel and Sufka (2001) demonstrated that an isolation stressor provoked depressive-like 
behavior in chicks.  
 
2.2.1.3 Mouse models of depression 
Several characteristics of mice are especially suitable for modelling illnesses that occur in 
humans: Mice are relatively easy to keep under laboratory conditions, and as mammals they 
share more similarities with humans than a non-mammal laboratory animal could offer. The 
majority of the genes in mice have a homolog in the human genome (Pollak et al., 2010). The 
mouse genome is accessible by gene-targeting and transgenic-techniques and the produced 
phenotype can be tested in behavioral tests that are standardized, commonly used and accept-
ed (Pollak et al., 2010). Simultaneously, mice have a relatively short generation time which 
makes it possible to test high numbers and breed mice individualized to particular needs. The 
high degree of genetic homogeneity in addition to possible variation in genes of interest facili-
tates the readout of conducted experiments. 
On a basis of growing knowledge about the pathogenesis of depression and its treatment,  
different approaches have been taken to create a rodent model of depression. Although it is 
not possible to model all the symptoms that can comprise a depressed episode in humans, 
different attempts show some success. In order to picture particular features of human behav-
ior and taking account of the biological mechanisms, research has addressed the genetic and 
environmental underlying background of depression in humans and tried to utilize the 
knowledge to induce depression in rodents.  
Depressive-like phenotypes of rodents can be induced by pharmacological or non-
pharmacological treatment as well as by genetic manipulations and some authors successfully 
created a strain which shows a gene and environment interaction (Table 2).  
 
 
More recent studies focus not only on the symptoms of depression in different species but also 
ask the question how a particular phenotype might be used to serve as a model for human de-
pression. Fureix et al. (2012) investigated the influence of chronic stress on domestic horses 
and Hymel and Sufka (2012) demonstrated that an isolation stressor provoked depressive-like 
behavior in chicks. 
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 Models of genetically modified mice 
The modulation of a particular protein has been remarkably useful in depression research. 
Several manipulations across various neurobiological systems that result in depressive-like 
phenotypes are established. 
 
 Models of pharmacologically induced depression  
Various drugs are able to provoke depressive-like behavior in rodents. The most commonly 
used assay to induce a depressive-like phenotype is the injection of pro-inflammatory drugs, 
namely lipopolysaccharide (LPS) or cytokines.  
LPS that induces the release of pro-inflammatory cytokines, as well as the immediate        
administration of cytokines, have been shown to interact with the immune system and there-
fore lead to a depressive-like phenotype.   
 
 Models of non-pharmacological induced depression 
Some attempts to create a model without the use of pharmacological substances show some 
success: 
 
o Olfactory bulbectomy 
This model is mostly used in rats and comprises the surgical removal of the olfactory 
bulbs with the consequence of increased open field activity, avoidance-learning deficits 
and alterations in the endocrine, immune and neurotransmitter system that correlate with 
many of the changes seen in depressed patients (Pollak et al., 2010).  
 
o Stress-induced depression 
Stress, as mentioned earlier, is able to cause depression in humans. Several paradigms 
have been established for rodents using the pathway to create an animal model of          
depression. The paradigm’s main strength is the clinical evidence that stressful life events 
can trigger depressive episodes in humans (Krishnan and Nestler, 2010).  
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o Maternal deprivation 
The separation of the mother from her pups within a period critical for physical and     
mental development has consequences for both individuals: The repeated deprivation of 
maternal care to the offspring affects the stress and depressive-like behavior later in life, 
whereas the mother displays inappropriate attention towards the pups and an increase in 
the level of anxiety and depressive-like behavior (Finamore and Port, 2000, Eklund et al., 
2009).  
 
o Learned helplessness 
After animals experience an uncontrollable and inescapable stress, for example exposure 
to inescapable electric shocks, they display an increased escape latency or complete    
failure to escape the re-exposure to the same event, even when provided with an easy    
escape route. The state of the animals is referred to as a state of “helplessness” (Seligman 
et al., 1975).  
The paradigm of learned helplessness has been established for research purposes because 
behavioral correlates of helplessness are seen frequently in depressed humans and due to 
its exclusive treatment response to antidepressant drugs (Pollak et al., 2010). 
However, a very variable amount of animals (10-80%) develop measurable behavioral 
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2.2.1.4 Behavioral tests for depression in rodents 
Several tests are thought to be particularly suitable to assess depression-related behavior in 
rodents, because they contain observations of depression as they are typically found in      
humans. In this section the most commonly used tests are mentioned. A more detailed       
description of these tests as well as additional tests that were performed to obtain a more ex-
tensive characterization of Gpm6b null mutants can be found in the “Material and Methods” 
section of this thesis. Despite the settings that are specifically designed to evaluate depressive-
like behavior, there are several other tests that are eligible to assess certain features of        
depression. Although these tests are not exclusively used for depression-related behavior, they 
are employed for a wide range of behavioral characterizations. The tests include assays for the 
measurement of altered levels of anxiety, locomotor activity or the assessment of the diurnal 
pattern, weight and feeding behavior.  
 
The first-generation of behavioral tests for depression were originally designed to detect   
responses to pharmacological antidepressants. Today, particularly the forced swim test and 
the tail suspension test are still most widely used because they are not expensive, easy to use 
and have a potentially high throughput (Pollak et al., 2010). 
 
 Forced Swim Test (FST) 
This assay was initially developed by Porsolt et al. (1977) to assess the effect of                 
antidepressants in rodents, but subsequently became the most popular behavioral test to assess 
depressive-like behavior. The behavior is measured as immobility time which is explained as 
behavioral despair (Pollak et al., 2010).  
 
 Tail Suspension Test (TST) 
Similar to the forced swim test, behavioral despair is assessed as the time spent immobile.  
Comparable to the forced swim test, a wide range of pharmacological antidepressants have 
been shown to reduce the time the mice spent immobile (Pollak et al., 2010). 
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 Measurements of anhedonia 
Anhedonia is one of the core symptoms of depression and is defined as “markedly diminished 
interest or pleasure in all, or almost all, activities most of the day, nearly every day” 
(American Psychiatric Association., 2000).  
Anhedonic behavior can be reliably reproduced and measured in rodents with two             
different tests: 
 
o Sucrose preference 
A reduced interest in sucrose solution is assumed to be an indicator for a reduction in the 
rewarding effectiveness (Jayatissa et al., 2006) in analogy to anhedonic behavior that is 
described in humans.  
 
o Intracranial self-stimulation  (ICSS) 
This paradigm can be reliably applied to mice and rats. The rodents have electrodes      
implanted into the brain and can self-administer rewarding electrical stimulation. The 
electrodes are implanted in brain regions that are associated with the rewarding process, 
such as the medial forebrain bundle at the level of the lateral hypothalamus (Slattery et al., 
2007). ICSS is used to evaluate depression-related behavior in various settings and to in-
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Zhu et al. (2010) 
de Paiva et al. 
(2010) 
 
Mouse OFT: reduced activity 
FST, TST: increased 
immobility  
EPM: increased anxiety  
feeding behavior: reduced 
food-intake 
 
Performances of different 
tests highly dependent on  
dose and testing interval 
after administration.  
 
Isotretinion     
treatment 
O'Reilly et al. 
(2006) 
Mouse TST, FST: increased 
immobility 
OFT: no differences 
=13-Cis-retinoic acid, 




































ICSS: increased brain 
reward thresholds 
FST: increased           
immobility 
 
TST: decresed immobility 
 






Model Author Species Relevant behavioral 
readouts 
Remarks 










Olfactory     
bulbectomy 
Review: Song and 
Leonard (2005) 
Rat Increased exploratory behavior, 
open field activity, open arms 
entries (EPM), nocturnal hyper-
activity 
Impaired Morris water maze 
behavior, food-motivated    





























preference, decrease in other 
hedonic behaviors, potentiation 
of learned helplessness,      
decreased male sexual behavior, 
decreased male aggression, 
decreased grooming, decreased 
REM sleep latency, increased 
immobility in the FST 
 
Decreased saccharin preference 
 
 





EPM: Increased anxiety-like 
behavior 
 
Maternal     
deprivation 









Disturbances of HPA axis  
 
Reduced ICSS  
 
Learned     
helplessness 




Altered REM sleep 
Reduced body weight, dimin-
ished sexual behavior,  elevated 
levels of CRF and               
corticosterone 
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GENETIC MODELS 
 













OFT, EPM: no effect of 
genotype 
TST: decreased immobility 
FST:  increased immobility 
Novelty suppressed feeding 
paradigm: increased anxiety 
 







TST: decreased immobility 
FST: increased immobility 
Reduced neuromus-
cular strengths may 
affect performance 
Analysis does not 
distinguish between 
males and females 








Locomotor activity: no 
effect of genotype  
TST: decreased immobility  
FST: no effect of genotype  
sucrose preference: no 
effect of genotype 
Mice showed a trend 
































OFT: decreased activity 




OFT: decreased activity, 
decreased center time 
TST: increased immobility 
Marble burying: decreased 
marble burying 
 
FST: increased immobility 
Fear conditioning, fear 
extinction: no effect of 
genotype 
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Holmes et al. 
(2003) 
 



















OFT: in both genders de-
creased horizontal/vertical 
activity and decreased  
center time 
EPM: in both genders de-
creased open arm entries 
and open arm time 
Light-dark-exploration test:  
Decrease of light-dark 
transitions, increase of time 
spent in dark compartment 
(females only) 
Emergence Test: Decrease 
of shelter-open field transi-
tions and increase of time 






General remark to 
SERT-KO mice:  
Conflicting results 
might be due to the 
genetic heterogeneity 
of different strains 
Increased anxiety 
can be observed 

























Open Field Test: no effect 
of genotype in horizontal 
activity 
Decreased rearing after 
exposure to injection 
stress 
Light-dark-box: increased 
anxiety after exposure to 
injection stress 
FST: increased immobility 
due to decreased climbing 
(not swimming) 
 
24 hour locomotor activity 
measurement: flattened 
pattern of activity  












FST: increased immobility  
 
 









FST: no effect of geno-
type in baseline immobili-
ty 
Blockade of antidepres-











OFT / homecage observa-
tion: decreased activity 
Light-dark-box: decreased 
activity, increased anxiety 
FST: increased immobility 
Fear conditioning:       de-
creased conditioned fear at 
1 h but not 24 h after condi-
tioning 
Impaired perfor-
mance on rotarod  
 
CRF2 – receptor 
knockout  
















Food intake: Decreased 
food intake following 24 h 




EPM / OFT: in both   gen-
ders increased anxiety 
Light-Dark-Box: No effect 
of genotype 








Wei et al. (2004) Mouse OFT: no effect of genotype 
FST: increased immobility 




and immobility is 
attenuated by anti-
depressants 
CB1  receptor 
knockout  
Review: Valverde 
and Torrens (2012) 
Mouse EPM, OFT, light-dark-box: 
increased anxiety 
Fear conditioning: impair-
ment of extinction  
Partner recognition test, 
Operant conditioning test,   
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TST: increased immobility 
Delta-opioid   
receptor knockout 
Filliol et al.(2000) Mouse EPM / Light-dark-box: 
increased anxiety 
FST: increased immobility 
 
p11 knockout  Svenningsson et 
al. (2006) 
Mouse Increased thigmotaxis 




ization of  5-HT1B 
receptors  
BDNF knockout Chan et al. (2006) Mouse TST: increased immobility 
FST: decreased immobility 
EPM: no effect of genotype 
 
 
MIXED MODELS (gene and environment) 
 
Model Author Species Relevant behavioral 
readouts 
Remarks 
5-HT: 5-hydroxytryptamine; BDNF: brain-derived neurotrophic factor; CB1 receptor: cannabinoid receptor type 
1; CRF: corticotropin releasing factor; EPM: elevated plus maze; FST: forced swim test; h: hour / hours; HPA: 
hypothalamus pituitary axis; KO: knockout; OFT: open field test; REM: rapid eye movement; SERT: serotonin 
transporter; TST: tail suspension test 
 
Table 2: Rodent models of depression 
α-2A – adrenore-
ceptor knockout   
+ stressor 





Decreased rearing after 
exposure to injection 
stress 
Light-dark-box: in-
creased anxiety after 







Bale et al. (2000) Mouse Decreased food intake 
after 24h lasting food 
deprivation  
No differences  in 
body weight 
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3 Objectives and hypothesis of the present thesis 
 
 
Disturbances of the serotonergic system are hypothesized to be a main pathway that may lead 
to the development of depression in humans.  
The use of Gpm6b null mutants in this thesis may indirectly illustrate the impact of M6B on 
the serotonin transporter of these mice. Since Gpm6b null mutants will not express any M6B, 
the inhibitory effect of the glycoprotein on the serotonin transporter is no longer present. Mice 
with a surface overexpression or increased function of the serotonin transporter are expected. 
This is hypothesized to lead to a more efficient clearing of serotonin from the synaptic cleft.  
An induced relative deficiency of serotonin in Gpm6b null mutants should provoke a         
depressive-like phenotype and provide interesting candidates for modelling depression in 
mice.  
Additionally to a general characterization of this mouse strain, different challenges will be 
performed. In order to prove the involvement of the serotonergic system, the response to the   
5-HT2A/2C receptor agonist (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochlo-
ride (DOI) of Gpm6b null mutants and wildtype mice will be compared.  
Furthermore, the pro-inflammatory substance lipopolysaccharide (LPS) will be applied to 
investigate a potential enhancement of a depressive-like phenotype.  
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4 Material and Methods 
 
4.1 Animals and housing 
For the behavioral tests male Gpm6b null mutants and their wildtype littermates were used. 
Mice were bred by the Department of Neurogenetics (Max Planck Institute of Experimental 
Medicine, Göttingen). The exact method of gene targeting and mouse genetics was described 
by Werner et al. (2013). Mice were bred on a C57BL/6J background for more than 10 genera-
tions but formally are a C57BL/6J*129SV hybrid (Werner et al., 2013). 
At the age of 21 days, mice were weaned and housed in groups of 4-5 animals in standard 
plastic cages (Tecniplast, type 1284L, 20 x 30 x 12 cm) with wood-chipped bedding (Retten-
meier FN 1-4). Each cage was equipped with a paper tissue, as well as food and water ad libi-
tum. The food consisted of pelleted complete feedingstuff (Ssniff V1124-3; dry matter 87,9%, 
raw protein 22%, raw fat 4,5%, raw fiber 3,9%, raw ash 6,8%, metabolizable energy 13,6 
MJ/kg). Tab water was provided in drinking bottles. The temperature in the colony room was 
maintained at 20-22 C, with 55 ± 5% air .humidity, and a 12 h light-dark cycle (light on at 
8:00 am) was applied. The cages were located in closed shelves that were part of a ventilation 
system to prevent infections.  
Mice got transferred to new cages every 7-10 days and food and water was checked every day 
and refilled as needed. The responsible person during the testing phase was the person con-
ducting the experiments. 
 
4.2 Behavioral testing 
All experiments were approved by the governmental Animal Care and Use Committee in   
accordance with the German Animal Protection Law.  
Behavioral experiments were conducted by an investigator, blinded to the genotype, during 
the light phase of the day (in general between 9:00 am and 6:00 pm). Age of mice at the be-
ginning of testing was 13-14 weeks. Inter-test interval was at least 1 day. Three different co-
horts of mice were used.  
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The order of testing of the first cohort was: elevated plus maze, open field, pre-pulse          
inhibition, rotarod, visual cliff, hearing, holeboard, hot plate, novel object recognition, social 
interaction and memory in the 3-compartement chamber, Morris water maze, chimney test, 
sucrose preference, olfaction / buried food finding, marble burying, tail suspension test, 
forced swim test, contextual and cued fear conditioning, DOI-project, LPS-project. 
The tests conducted with the second cohort were: hearing, prepulse inhibition, DOI-project. 
The third cohort was used for the following tests: LABORAS, hearing, prepulse inhibition, 
fear extinction curve. 
All basic behavior tests were performed in accordance to the behavioral protocols of the    
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4.3 Genotyping 
To identify the genotype of the mice, tail biopsies were taken prior to testing and analyzed by 
the Department of Neurogenetics (Max Planck Institute of Experimental Medicine, Göttin-
gen) using a genotyping protocol based on polymerase chain reaction (PCR). The M6B 
knockout allele can be discriminated from the wildtype allele with a three primer PCR (for 
primer sequences see Fig. 4b).  
The first primer, M6B.P38.AS, is an antisense primer located in the M6B exon, encoding the 
first transmembrane domain (exon 4) in a position that is replaced by neo in the knockout. 
The second primer, M6B.P62, is located in Intron 3. P62 together with P38 produce an ampli-
fication product of app. 400 bp for the wildtype allele (Fig. 4a). P62 together with the third 
















Table 3: Genotyping protocol used for genotyping Gpm6b null mutants 
Protocol: 
1 μl dissolved tail DNA 
0.375 μl P38 (10 pmol/μl stock) 
0.75 μl P62 (10 pmol/μl stock) 
0.75 μl neo6 (10 pmol/μl stock) 
0.2 mM dNTPs 
1x Red Taq Puffer 
0.5 μl Red Taq (Sigma) 
ad H2O 
total: 20 μl 
 
36 cycles of:  
Annealing 30 sec 56 °C 
Elongation 60 sec 72 °C 
Denaturation 30 sec 95 °C 
Run on agarose gel (1-2%) 
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M6B.P38.AS 5‘-CCAGGGAGGCATAGGGAACT-3‘  
M6B.P62 5‘-CCCTTTGCCTCCCAGTCAGTTG-3‘  
neo6 5‘-GCAATCCATCTTGTTCAATGGC-3‘  
 
Figure 4: (a) Agarose gel with amplification products for knockout and wildtype alleles          










KO      WT         HET (a) 
(b) 
~ 700 bp (knockout allele) 
~ 400 bp (wildtype allele) 
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4.4 Behavioral tests  
 
4.4.1 Basic behavior testing 
 
4.4.1.1 Elevated plus maze 
In this test of anxiety, a maze made of grey plastic with a 5x5 cm central platform, two      
30x5 cm open arms and two 30x5x15 cm closed arms was used and an illumination 120 lx 
was applied. Mice were placed in the central platform, facing an open arm of the maze.    
Subsequently, behavior was recorded for 5 min by an overhead video camera and a PC 
equipped with “Viewer 2” software (Biobserve GmbH, Bonn, Germany) to calculate the time 
spent in open or closed arms, number of arm visits as well as distance traveled and velocity. 
 
4.4.1.2 Open field  
Spontaneous activity in the open field was tested in a grey Perspex arena (120 cm in diameter, 
25 cm high; illumination 120 lx). Mice were placed in the center and allowed to explore the 
arena for 7 min. The behavior was recorded by a PC-linked overhead video camera. “Viewer 
2” software was used to calculate distance traveled, velocity and time spent in central, inter-
mediate or peripheral zones of the open field. 
 
4.4.1.3 Rotarod  
The rotarod test assesses motor function, coordination and balance. The test consisted of a 
rotating drum (Ugo Basile, Comerio, Varese, Italy), which was accelerated from 4 to 40 
rounds per min over the duration of 5 min. Mice were placed individually on the drum and the 
latency of falling off was recorded using a stop-watch. To evaluate motor learning, the rotarod 
test was repeated 24 h after the initial trial. 
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4.4.1.4 Visual cliff  
The test was used to examine visual deficiencies of the mice. The test apparatus was        
comprised of an open-topped box (70 × 35 cm floor, 30 cm high). The base consisted of clear  
Perspex and the walls of the box were made from white Perspex.  
The box was placed on the edge of a laboratory bench with the consequence that half of the 
base was positioned on the bench ("ground” side), and the other half over the edge of the 
bench, suspended 1 meter above the floor ("air” side). Mice were then individually placed in 
the middle of the base at the edge of the cliff. The activity was assessed for 5 min by a com-
puter using video-tracking system Viewer 2 (Biobserve GmbH, Bonn, Germany). The per-
centage of time mice spent on the “ground” and the “air” side of the box was calculated. 
 
4.4.1.5 Holeboard  
The holeboard test, to measure exploratory activity, consisted of a 51×51×33 cm transparent 
Perspex chamber with a non-transparent floor that was equipped with 16 equally spaced 
holes, each 2 cm in diameter and 2 cm deep. Mice were allowed to freely explore the appa-
ratus for 5 min and the number of explored holes (measured as nose pokes) was registered by 
a computer software (TSE GmbH, Bad Homburg, Germany). The illumination in the testing 
room was 120 lx. 
 
4.4.1.6 Hot plate  
The hot plate test was used as a measure of pain sensitivity. Mice were placed on a metal 
plate (Ugo Basile) that was preheated up to 55 °C. The latency till the mice showed either 
hind paw licking or jumping was recorded. Immediately after showing the response mice 
were removed from the platform. 40 sec cut-off time was supposed to prevent wounds, alt-
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4.4.1.7 Marble burying 
The marble burying and digging test measures impulsive and stereotyped behavior in rodents. 
The test box (34.5x56.5x18.5 cm) is filled with relatively deep bedding (about 5 cm) and the 
surface is smoothened. Marbles are set in a grid-like pattern using a cardboard template, 
which is removed prior to testing. Mice are put in the chamber for 30 min and allowed to 
freely explore. The number of buried marbles in both the periphery (16 edge marbles) and the 
center (8 middle marbles) is quantified. Marbles are considered buried if at least two-thirds of 
the marble is obscured from view. 
 
4.4.1.8 Olfaction / Buried food finding   
Starting 4 days prior to testing, mice received several pieces of chocolate cookies of 1.6 g 
daily with water ad libitum. All mice consumed all cookies within 24 h. Then, mice were de-
prived of food for 12 h before testing, with water ad libitum. For testing, individual mice were 
placed into clear cages (29.5x18.5x13 cm), in which a piece of a chocolate cookie was posi-
tioned at the end of the cage. The mouse was put in the right corner at the opposite end of the 
cage, and the food-finding time, i.e. the time from the moment the mouse was placed into the 
cage to the time it arrived at the cookie, was recorded. In a second trial the cookie was hidden 
under 1.5 cm standard bedding instead of being visible and the time the mouse needed to find 
the cookie, e.g. started digging, was recorded. As soon as the cookie was uncovered, the 
mouse was removed from the cage. A fresh cage and bedding was used for each trial, and all 
mice were subjected to identical testing procedures. 
 
4.4.1.9 Hearing  
The hearing test used the same apparatus as for assessment of the prepulse inhibition.         
The startle reaction to an acoustic stimulus (pulse), which evokes a movement of the platform 
and a transient force resulting from this movement of the platform, was recorded with a com-
puter during a recording window of 100 ms and stored for further evaluation. The recording 
window was defined from the onset of the acoustic stimulus. An experimental session        
consisted of 2 min habituation to 65 dB background white noise (continuous throughout the 
session), followed by a baseline recording for 1 min at background noise. After baseline    
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recording, stimuli of different intensity and fixed 40 ms duration were presented. Stimulus 
intensity was varied between 65 dB and 120 dB, such that 19 intensities from this range were 
used with 3 dB steps. Stimuli of each intensity were presented 10 times in a pseudorandom 
order with an interval ranging from 8 to 22 sec. The amplitude of the startle response (ex-
pressed in arbitrary units) was defined as the difference between the maximum force detected 
during a recording window and the force measured immediately before the stimulus onset. 
Amplitudes of responses for each stimulus intensity were averaged for individual animals.  
 
4.4.1.10 Prepulse inhibition  
For this test of sensorimotor gating, individual mice were placed in small metal cages 
(90x40x40 mm) to restrict major movements and exploratory behavior. The movable platform 
floor of each cage was attached to a sensor that records vertical movements of the floor. The 
cages were placed in sound-attenuating isolation cabinets (TSE GmbH, Bad Homburg,    
Germany). Startle responses were evoked by acoustic stimuli delivered from a loudspeaker      
suspended above the cage and connected to an acoustic generator.  
The startle reflex to an acoustic stimulus evokes a movement of the platform and a transient 
force resulting from the movement. The reaction was recorded with a computer during a time 
window of 260 ms (beginning with the onset of prepulse) and stored for further evaluation. 
The recording window was defined from the onset of the acoustic stimulus.  
An experimental session consisted of a habituation period of 2 min to 65 dB background 
white noise (continuous throughout the session), followed by a baseline recording for 1 min at 
background noise. After baseline recording, 6 pulse-alone trials using startle stimuli of 120 
dB intensity and 40 ms duration were applied in order to decrease influence of within-session 
habituation. These data were not included in the analysis of the prepulse inhibition. For tests 
of prepulse inhibition, the 120 dB / 40 ms startle pulse was applied either alone or preceded 
by a prepulse stimulus of 70 db, 75 db, or 80 dB sound pressure level and 20 ms duration. An 
interval of 100 ms with background white noise was applied between each pre-pulse and 
pulse stimulus. The trials were presented in a pseudorandom order with an interval ranging 
from 8 to 22 sec. The amplitude of the startle response (expressed in arbitrary units) was de-
fined as the difference between the maximum force detected during a recording window and 
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the force measured immediately before the stimulus onset. Amplitudes were averaged for 
each individual animal, separately for both types of trials (i.e. stimulus alone or stimulus pre-
ceded by a prepulse). Pre-pulse inhibition was calculated as the percentage of the startle re-
sponse using the following formula: % pre-pulse inhibition = 100 – [(startle amplitude after 
pre-pulse and pulse) / (startle amplitude after pulse only) x 100]. 
 
4.4.2 Social behavior testing 
 
4.4.2.1 Social interaction and memory in the 3-compartement chamber  
The social testing arena was a rectangular, 3-chambered box. Each chamber was       
20x40x22 cm in size. Dividing walls were made from clear Plexiglas, with rectangular open-
ings (35x35 mm) allowing access into each chamber. The chambers of the arena were 
cleaned, and fresh paper chip bedding was added between trials. The test mouse was first 
placed in the middle chamber and allowed to explore for 5 min. The openings into the two-
side chambers were obstructed by plastic boxes during this habituation phase.  
After the habituation period, an unfamiliar C57BL/6 male mouse without prior contact to the 
subject mouse was placed in one of the side chambers. The location of the stranger mouse in 
the left versus right side chamber was systematically alternated between trials. The stranger 
mouse was enclosed in a small (60x60x100 mm), rectangular wire cage which allowed nose 
contact through the bars but prevented fighting. The animals serving as strangers had previ-
ously been habituated to placement in the small cage. An identical empty wire cage was 
placed in the opposite chamber. A heavy cup was placed on top of each of the small wire cag-
es to prevent climbing by the test mice. Both openings to the side chambers were then un-
blocked, and the subject mouse was allowed to explore the entire social test arena for a 10-
min-session. The amount of time spent in each chamber was recorded by the video tracking 
system “Viewer 2” (Biobserve GmbH).  
A second, unfamiliar mouse was then placed into the previously empty wire cage. The test 
mouse had a choice between the first, already explored mouse (familiar), and the novel unfa-
miliar mouse (stranger). As described above, measures were taken of the amount of time 
spent in each chamber during the second 10-min-session.  
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4.4.3 Learning and memory testing 
 
4.4.3.1 Novel object recognition    
The object recognition test is based on the natural tendency of mice to investigate a novel 
object instead of a familiar one. The choice to explore the novel object reflects the use of 
learning memory. 
In the object recognition task, a mouse was placed in a box and was exposed for 10 min to 
two objects (object1 and object2) that were similar in shape and colour and were located a 
specified distance from each other. The mouse was then removed from the environment and 
immediately after the exploration period testing takes place. The mouse was retested in the 
same environment for 10 min except that one of the two previously used (familiar) objects 
was replaced with a novel one that differs from the familiar object in shape and appearance. 
A week later the mice were again exposed to two similar objects (object1 and object2) and 
allowed to explore freely. After removing the mice from the environment a delay of 30 min 
was awaited before the mice were returned to the box with one familiar and one novel object. 
The behavior was recorded by a video/computer controlled system which measures the   
number of visits and the duration mice spent on exploring the objects. Subsequently,        
preference for each object was calculated. 
 
4.4.3.2 Morris water maze    
Spatial learning and memory was assessed in a water maze. A large circular tank (diameter 
1.2 m, depth 0.4 m) was filled with opaque water (25±1 ˚C, depth 0.3 m) and the escape plat-
form (10x10 cm) was submerged 1 cm below the surface. The swim patterns were monitored 
by a computer and the video-tracking system “Viewer 2”. The escape latency, swim speed, 
path length, and trajectory of swimming were recorded for each mouse. Every day, mice went 
through 4 trials with an inter-trial interval of 5 min. 
During the first 2 days, mice were trained to swim to a clearly visible platform (visible plat-
form task) that was marked with a 15 cm high black flag and placed pseudo-randomly in dif-
ferent locations across trials (non-spatial training). The extra-maze cues were hidden during 
these trials.  
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After 2 days of visible platform training, hidden platform training (spatial training) was per-
formed. For 8 days, mice were trained to find a hidden platform (i.e. the flag was removed) 
that was located in the center of one of the four quadrants of the pool. The location of the plat-
form was fixed throughout testing. Mice had to navigate using extra-maze cues that were 
placed on the walls of the testing room. The mice were placed into the pool facing the side 
wall randomly at one of four start locations and allowed to swim until they found the plat-
form, or for a maximum of 90 sec. Any mouse that failed to find the platform within 90 sec 
was guided to the platform. The animal then remained on the platform for 20 sec before being 
removed from the pool.  
The day after completion of the hidden platform training, a probe trial was conducted in order 
to determine whether mice used a spatial strategy to find the platform or not. The platform 
was removed from the pool and the mice were allowed to swim freely for 90 sec. The per-
centage of time spent in each quadrant of the pool was recorded.  
To investigate the flexibility of cognitive processes in mice, the reversal water maze test was 
performed. The experimental procedure was identical to the one used for the hidden platform 
training with the exception that the escape platform was moved from the original position to 
the neighboring quadrant. The reversal task was performed on 4 days and subsequently a re-
versal probe trial was conducted as described earlier.  
 
4.4.3.3 Contextual and cued fear conditioning   
For fear conditioning mice were trained within the same session for context and cue. Training 
consisted of exposing mice for 120 sec to the context to assess the baseline level of activity. 
This period was followed by a 10 sec, 5 kHz, 85 dB tone (conditioned stimulus, CS). Immedi-
ately after the tone, a 2 sec, 0.4 mA foot shock (unconditioned stimulus, US) was applied. 
This CS-US pairing was repeated 13 sec later. All mice remained in the conditioning cham-
bers (interior: 305x241x210 mm) for an additional 23 sec following the second CS–US pair-
ing. The contextual memory test was performed 48 h after this training. Mice were monitored 
over 2 min for freezing in the same context as used for training. The cued memory test was 
performed 52 h after training in a new chamber. First, mice were monitored for freezing over 
a 2 min pre-cue period with no tone to assess freezing in the new context. Next, a 2 min     
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lasting cue period followed in which the tone was presented. Duration of freezing behavior, 
defined as the absolute lack of movement (excluding respiratory movements), was recorded 
by a video camera and a PC equipped with ‘Video freeze’ software (MED Associates, St. Al-
bans, Vermont, USA). 
 
4.4.3.4 Fear conditioning – extinction curve 
Mice underwent the fear conditioning training as described above. 24 h later mice were     
exposed to the same context they experienced during the training and freezing levels were 
assessed. Subsequently, the animals were tested in the same context repeatedly in order to 
obtain an extinction curve.  
 
 
4.4.4 Tests for depressive-like behavior 
 
4.4.4.1 Sucrose preference   
The sucrose preference test was performed using a two-bottle procedure, during which mice 
had free access to both water and a sucrose solution. Animals were first habituated for 48 h to 
consume water from the 2 small (100 ml) bottles. After habituation, mice were deprived of 
water and the sucrose preference was measured during the next 4 days. The first 2 days served 
as a habituation to sucrose solution. The average consumption of sucrose solution in compari-
son to the amount of water consumed in the 4 days was used for the evaluation of sucrose 
preference. Each day, group-housed mice were placed individually into small plastic cages 
and 2 bottles were presented to them for 60 min - one with tap water and one with a 2% su-
crose solution. Consumption of water or sucrose solution was measured by weighing the bot-
tles before and after the session. Bottles were counterbalanced across the left and the right 
sides of the cage, and their position was alternated from test to test. Sucrose preference (per-
cent) was calculated as follows:   
Preference [%] = [sucrose solution intake (ml) / total fluid intake (ml)] × 100 
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4.4.4.2 Chimney test  
The chimney test measures whether a mouse can escape an inverted tube by climbing back-
wards. This model serves as a metric for neurological impairment and motoric functions, but 
also for the investigation of a lack of motivation to escape.  
No training is required for the task. Mice crawl into a horizontal tube, which is inverted. 
Normally, mice will attempt to escape by climbing backwards out of the space. The escape 
latency of the mice was recorded.  
 
4.4.4.3 Tail suspension test 
In the tail suspension test a tape gets attached to the mice’s tail (about 1 cm from the tip), and 
the tape is hung up on a bar so that mice are midair. Then the movements are recorded for 6 
min by a video camera and analyzed by trained observers. Typically, mice will initially strug-
gle in an attempt to escape and subsequently begin to remain motionless after having “given 
up” their efforts.  
 
4.4.4.4 Forced swim test  
The forced swim test assays for depression in a similar manner to the tail suspension test. 
Mice are placed in a clear container with ~25 ºC water and video-recorded over the duration 
of the trial (6 min). The time the mouse remains immobile is scored by trained observers. 
Immobility is defined as floating or small movements that allow the mouse to keep the head 
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climbing, grooming, eating, drinking, locomotion, scratching and seizure.  
LABORAS also tracks the positional information and speed of test animals.                       
During LABORAS recording, mice are housed in clear polycarbonate cages (Makrolon type 
II cage, 22x16x14 cm) that are directly placed onto the platform and have a wood-chip     
bedding covered floor as well as food and water provided. 
For the assessment of home cage behavior, mice were habituated to the room under single 
housed conditions on 2 consecutive days prior to testing. On day 3 mice were placed in the 
LABORAS cages 2 h before the dark phase. They remained undisturbed for 15 h and were 








“Laboratory Animal Behavior Observation              
Registration and Analysis System” 
The LABORAS system (Metris b.v., 
Hoofddorp, The Netherlands) characterizes 
and records rodent behavior through analysis 
of movement-induced forces generated by the 
animals. The system consists of a triangular 
shaped sensor platform (Carbon Fiber Plate 
1000x700x700x30 mm, Metris b.v.). The sen-
sors on the measurement plate amplify and 
match vibrations to stereotyped profiles of 
known actions. Recognized actions include  
 
 
Figure 5:  
Specific vibration patterns of 
rodent behavior analyzed with 
the LABORAS system 
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4.4.5 DOI – Project 
 
4.4.5.1 Pilot experiment 
The 5-HT2A/2C receptor agonist (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydro-
chloride (DOI) was purchased from Sigma-Aldrich (Germany) and dissolved in 0.9%         
sodium chloride solution.  
10 wildtype mice were used in the pilot project to assess the optimal dose of DOI provoking 
changes in distinct behavioral patterns, such as grooming and locomotion. One mouse at a 
time was removed from its cage, gently weighted and placed in a cage that was part of the 
LABORAS system and located in an undisturbed and lit room. Subsequently, the mouse was 
left alone for 30 min while its behavior was recorded by a video camera and LABORAS in 
order to assess its behavior without any manipulations. 
After 30 min the mouse was removed from the observation cage and either injected with a 
dose of 0.5 mg/kg DOI i.p. or 0.75 mg/kg DOI i.p.. Immediately after the injection, the mouse 
was returned to the observation cage and remained undisturbed for another 30 min.   
Grooming behavior was scored from video recordings and data for locomotor activity was 
obtained from LABORAS. The sessions were divided into 3 parts (each 10 min) that were 
rated separately and scored how much time the mouse spent revealing a particular behavior. 
 
4.4.5.2 Final protocol 
After identifying a suitable dose of DOI, wildtype mice and Gpm6b null mutants were used to 
assess potential variations in the grooming duration and locomotor activity in dependence of 
the genotype. The hypothesis was that Gpm6b null mutants show a different reaction to DOI 
than wildtype mice due to altered extracellular serotonin levels. 
Each mouse underwent the same procedure as described previously, but this time all mice 
received the same dose of DOI (0.5 mg/kg) i.p.. Video recordings and LABORAS data were 
analyzed as described previously.  
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4.4.6 LPS – Project 
 
4.4.6.1 Pilot experiment 
In order to challenge the mice pharmacologically, lipopolysaccharide (LPS) extracted from  
E. coli, was injected to elderly Gpm6b null mutants and wildtype mice. The aim was to find a 
threshold dose of LPS that increases the slightly depressive-like phenotype observed in 
Gpm6b null mutants during previous testing. Lipopolysaccharide was purchased from Sigma-
Aldrich and dissolved for injection in 0.9% sodium chloride solution. 
The protocol used for this project is illustrated in Figure 6. For the first approach, wildtype 
mice and Gpm6b null mutants (at the age of about 15.5 months) received a single i.p.-
injection of lipopolysaccharide at a dosage of 100 µg/kg body weight. 24 h later, mice were 
tested in the open field for a period of 6 min to detect potential sickness behavior, revealed as 
reduced locomotor activity. If no reduced locomotor activity was observable and it could 
therefore be assumed that mice had overcome the induced sickness, they were given a 1-h rest 
before performing the tests for depressive-like behavior. 50% of the mice performed the 
forced swim test and the other 50% underwent the tail suspension test. The allocation of the 
genotypes was evenly distributed. After a break of 6 h the mice were tested in the opposing 
test. 
 
4.4.6.2 Final protocol 
A dose of 100 µg/kg LPS did not prove to be adequate, since it did not have any effect on 
neither wildtype nor Gpm6b null mutants. Therefore, wildtype mice and Gpm6b null mutants 
(at the age of about 17 months) were injected i.p. with a dose of 250 µg/kg LPS on two     
consecutive days. After the injection the same protocol as used in the pilot project was em-
ployed (Fig. 6). The locomotor activity was assessed repeatedly (24 h, 48 h and 96 h after the 
second injection) for 6 min in the open field until no reduction of activity was observable. 
After the open field test mice were given a rest of 1 h before proceeding with the forced swim 
test and the tail suspension test as described previously.  
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4.3  Statistical analysis 
 
Unless stated otherwise, the results are expressed as mean±SEM and a p-value below 0.05 
was considered to be significant.  
The data were analyzed mainly using Prism4 (GraphPad Software, San Diego, CA, USA) and 
SPSS Software to compare the data by 2- or 3-way analysis of variance (ANOVA) with post-
hoc planned comparisons, or by ANOVA for repeated measurements, respectively Mann-
Whitney U and student t-test where appropriate.  
In the forced swim test, a mouse was excluded from the analysis when it was not able to swim 
properly (e.g. repeatedly sank to the ground).   
In the graphs shown in the result section, wildtype mice are referred to as “WT” and Gpm6b 
null mutants are referred to as “KO”.  
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5 Results 
5.1 Basic behavior testing  
– Differences only in the elevated plus maze and prepulse inhibition test 
 
The basic behavior testing shows that Gpm6b null mutants only differed from the wildtype   
littermates in the elevated plus maze and prepulse inhibition test. 
 
In the elevated plus maze (EPM) test (Fig. 7a - 7e) all mice spent significantly less time in the 
open arms than in the closed arms (Fig. 7a; p < 0.001) and an equal amount of time in the 
center of the EPM (Fig. 7b; p > 0.05), independent of the genotype.  
Assessment of the total number of visits revealed that Gpm6b null mutants visited the open 
arms as well as the closed arms more often than wildtype mice (Fig. 7d; p = 0.028) which was 
also reflected by a significantly higher amount of total arm entries (Fig. 7e; p = 0.0204). Both 
genotypes preferred to visit the closed arms rather than the open arms, which could be seen as 
a higher number of closed arm entries compared to open arm entries (Fig. 7d; p < 0.001). 
The velocity that was measured could show that Gpm6b null mutants traveled a significantly 
higher distance per second than wildtype mice (Fig. 7c; p = 0.0297). 
 
In the open field test (OFT) (Fig. 7f – 7i) both genotypes spent most of the time in the periph-
ery and less time in the intermediate or the central section (Fig. 7f). 
There was no significant difference in the number of center visits during the testing period     
between the genotypes (Fig. 7g); p > 0.05). It is interesting to note that Gpm6b null mutants 
had the tendency of a higher velocity in comparison to wildtype mice (Fig. 7j; p = 0.1577). 
Also, the total distance traveled tended to be greater in Gpm6b null mutants (Fig. 7h; p = 
0.1611). These results point in the same direction as those of the EPM, i.e. underscore a mild 

















































































Figure 7: Gpm6b null mutants 
show significantly increased veloc-
ity in the EPM and the tendency of 
enhanced activity in the OFT 
 
(a) – (e)  EPM 
(a) Time spent in arms (b) Time 
spent in center  (c) Average veloci-
ty (d) Number of visits of open and 
closed arms (e) Number of total 
visits 
n = KO 18; WT 16 
 
(f) – (i) OFT 
(f) Time spent in different zones 
(g) Number of center visits (h) 
Total distance traveled (i) Average 
velocity 




*p < 0.05 WT vs. KO 
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p < 0.001 closed vs. open arm   
entries   
 
 
      ### 
























  *  




























     / ### 












































































































- 45 - 
 Results 
The results of the rotarod (Fig. 8a) show that there was no initial difference in the genotype 
with regard to motor functions (genotype: p > 0.05) and that both genotypes were able to im-
prove their performance when tested again 24 h later (day: p < 0.004). Therefore, it can be 
concluded that Gpm6b null mutants do not have impairments in motor functions or motor 
learning. 
 
When analyzing the data from the visual cliff test (Fig. 8b), there was no significant differ-
ence between the genotypes observable (p > 0.05). Both genotypes preferred staying on the 
ground side of the box which indicates an unimpaired vision of Gpm6b null mutants. 
 
The exploratory activity, measured by the number of nose pokes that the mice showed in the 
holeboard test (Fig. 8c), did not yield any differences between genotypes (p > 0.05).  
 
The data obtained from the hot plate test (Fig. 8d) for testing reaction to pain revealed that 
there were no differences between Gpm6b null mutants and wildtype mice (p > 0.05). Both 
genotypes showed signs of pain after a similar duration spent on the hot plate.  
 
Assessing the motor impulsivity and stereotypy with the marble burying test (Fig. 8e)        
revealed that there were no differences in Gpm6b null mutants as compared to wildtype     
littermates in the number of buried marbles (p > 0.05). 
 
In the buried food finding test (Fig. 8f) both genotypes were faster finding the visible cookie 
than discovering the hidden one. Independent of the differences between the visible and the 
hidden cookie, the performance of Gpm6b null mutants was comparable to the performance 
of wildtype mice (p > 0.05), excluding an applicable olfactory deficit. 
 
The hearing ability (Fig. 8g) of the mice did not show any significant difference (p > 0.05). 
Also, the body weight of the different genotypes (Figure 8h) was comparable (p > 0.05) and 
therefore did not influence the outcome of the test. 






















Figure 8: No abnormalities of Gpm6b null mutants in various basic tests 
(a) Latency time on rotarod (b) Percentage of time spent on the ground side of the visual cliff  (c) 
Number of nose pokes in the holeboard test (d) Latency until observable pain reaction on the hot plate 
(e) Number of buried marbles (f) Time needed to find the cookie (g) Hearing capabilities (h) Body 
weight at the time of hearing assessment 
(a) n = KO 19; WT 15   (b)-(e) n = KO 19; WT 16   (f)+(h) n = KO 36; WT 39 
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In the prepulse inhibition test (Fig. 9b) Gpm6b null mutants showed a reduction compared to 
wildtype mice (p = 0.013). All mice showed a significantly different inhibition of their      
response after the prepulse dependent on the sound intensity (p < 0.001). There was, however, 
no interaction of genotype and sound intensity present (p > 0.05). 
Neither the startle response (Fig. 9a) nor the body weight at the time of the prepulse inhibition 
test (data not shown) differed between Gpm6b null mutants and wildtype mice (p > 0.05) 
which is essential because both factors could otherwise affect the outcome of the prepulse 









Figure 9: Unaltered startle response but reduced prepulse inhibition of Gpm6b null mutants 
(a) Startle response (b) Percentage of prepulse inhibition   
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5.2 Social behavior testing  
– No differences in social interaction and social memory in Gpm6b null mutants 
 
The results of the social interaction and memory test revealed that both genotypes preferred to 
interact with an unfamiliar mouse instead of spending time in the compartment with the     
empty cage (Fig. 10a). The amount of time mice spent in the compartment equipped with the 
stranger was significantly higher than the duration mice spent in the empty compartment       
(p < 0.001). When mice had the choice to interact with either a familiar mouse or with an un-
familiar mouse (Fig. 10b), both genotypes preferred to explore the new mouse, reflected in a 
greater time amount they spent in the chamber with that mouse (p = 0.0017).  
It can be summarized that Gpm6b null mutants do not have any differences with regard to 









Figure 10: Normal social behavior of Gpm6b null mutants 
(a) Interaction time with stranger mouse as compared to empty compartment (b) Interaction time with 
familiar mouse as compared to stranger mouse 
n = KO 19;  WT 16 
###
p < 0.001 mouse vs. empty compartment   
##
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5.3 Learning and memory testing 
- Gpm6b null mutants show hints of an enhanced fear memory but no further            
alterations in learning and memory tasks 
 
During the first trial of the novel object recognition test, in which two identical objects could 
be explored by the mice, both genotypes spent about 50% exploring either of the objects (Fig. 
11a).  
In the following session with no delay (Fig. 11b + 11c) mice spent significantly more time 
exploring the novel object, which resulted in an increased number of visits (Fig. 11c;               
p = 0.002) and a longer duration of time exploring the novel object (Fig. 11b; p = 0.002) 
without a genotype effect being observable (p > 0.05). 
During the object exploration trial that was performed about 1 week later (Fig. 10d) wildtype 
mice preferred exploring object1 (p = 0.0047), whereas Gpm6b null mutants explored both 
objects equally. However, after a delay of 30 min all mice seemed to prefer spending time 
with the unfamiliar object which is reflected in a recognition index of about 60% for both 




























Figure 11: The recognition of a familiar object did not show any variances of Gpm6b null mutants 
compared to wildtype mice 
(a) Percentage of interaction time with object1 and object2  (b) Percentage of time spent with new and 
familiar object when no delay was applied after the exploration trial  (c) Number of visits of new and 
familiar object when no delay was applied after the exploration trial  (d) Percentage of interaction time 
with object1 and object2  (e) Percentage of time spent with new and familiar object when a 30 min 
delay was applied after the exploration trial    
##p < 0.01 familiar object vs. new object 
++p < 0.01 exploration time of object1 vs. object2 in wildtype mice 
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The Morris water maze (Fig. 12a – 12g) as a test for spatial learning and memory did not 
show any significant differences between Gpm6b null mutants and wildtype mice.  
In the visible platform task performed on two consecutive days (Fig. 12a), the duration 
Gpm6b null mutants needed to reach the platform was similar to the time wildtype mice re-
quired (p > 0.05).  
The performance of Gpm6b null mutants in all other trials that measured spatial learning and 
memory was similar to the ones wildtype mice displayed. In the hidden platform training, 
where spatial training was performed, both genotypes learned where to find the new location 
of the platform equally so that the resulting duration curve needed of reaching the platform is 
almost identical (Fig. 12b). The distance traveled before finding the platform (Fig. 12c) and 
the average velocity during the search for the platform (Fig. 12d) did not show any differ-
ences between genotypes (p > 0.05). Subsequently, both genotypes spent the same amount of 
time searching in the quadrant where the platform used to be during the spatial training     
(Fig. 12e; p > 0.05).  
When the platform was positioned in a different quadrant during the reversal water maze test 
(Fig. 12f), the duration Gpm6b null mutants required to reach the platform did not show any 
differences as compared to the performance of wildtype mice (p > 0.05). 
Also, there was no significant difference between Gpm6b null mutants and wildtype mice 
when the platform was again removed from the tank (Fig. 12g): Both genotypes spent the 
same amount of time in the quadrant where the platform had been previously during reversal 
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Figure 12: No differences in the Morris water maze task  
(a) Time needed to reach the visible platform (b) Time needed to 
reach the hidden platform (c) Distance traveled until finding the 
hidden platform (d) Average velocity when searching for the hidden 
platform (e) Percentage of time spent in quadrant (f) Time needed 
to reach the platform when moved to another quadrant (g) Percent-
age of time spent in quadrant 
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In the fear conditioning test (Fig. 13a) all mice showed a comparable baseline freezing level 
(p > 0.05). When exposed to the same context 48 h later, Gpm6b null mutants showed a sig-
nificantly higher amount of time freezing as compared to wildtype mice (p = 0.04).  
The freezing level that was obtained in another context before and after the mice could hear 
the tone (basecue and cue, respectively) did not show any differences between Gpm6b null 
mutants and wildtype mice (p > 0.05). 
 
In contrast to the initially obtained fear conditioning results, the fear extinction curve        
(Fig. 13c) that was assessed with another cohort of mice starting 24 h after conditioning, did 
not show impairments in fear extinction of Gpm6b null mutants. Gpm6b null mutants had a 
similar course of reduction in freezing behavior as wildtype mice when exposed to the same 
context repeatedly without experiencing the foot shock (p > 0.05). The baseline freezing was 
again not altered (Fig. 13b; p > 0.05). 
Comparing the freezing levels of the first exposure to the same context after the training    
session (Fig. 13d), it could be shown that Gpm6b null mutants spent about 60% of the time 
freezing in both protocols (24 h and 48 h after conditioning, respectively) (p > 0.05), whereas 
wildtype mice revealed a reduced freezing when the interval between the training and the con-



































Figure 13: Hints for a prolonged contextual fear memory 
(a) Freezing levels of initial fear conditioning (b) Baseline freezing level for extinction curve  (c) Fear 
extinction curve (d) Freezing level at time of first exposure to context 
(a) n = KO 17; WT 16  (b) – (c) n = KO 16; WT 18                
*p < 0.05 WT vs. KO;  #p < 0.05 WT 24 h vs. 48 h 
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5.4 Tests for depressive-like behavior  
– Gpm6b null mutants exhibited an increased immobility time in the FST 
 
Gpm6b null mutants displayed a strong sucrose preference (about 80%) and therefore did not 
show any significant differences to wildtype mice (Fig. 14a; p > 0.05). 
 
In the chimney test (Fig. 14b) the performance of Gpm6b null mutants did not show any    
differences as compared to the performance of wildtype mice (p > 0.05). Both genotypes  
escaped the tube in less than 30 sec. 
 
The tail suspension test (TST) (Fig. 14c) did not reveal any significant differences between 
Gpm6b null mutants and wildtype mice. Both genotypes spent the same time immobile during 
the trial (p > 0.05). 
 
In the forced swim test (FST) (Fig. 14d) Gpm6b null mutants spent significantly more time 
immobile than wildtype mice (p = 0.033). 
 
The LABORAS analysis (Fig. 15a - 15e) revealed that there is no difference in the assessed 
parameters between genotypes. None of the assessed parameters (locomotion, immobility, 
climbing, eating, grooming) did show any significant difference between wildtype mice and 
























Figure 14: The forced swim test revealed a significant difference between genotypes 
(a) Preference for sucrose solution  (b) Time needed to escape the inverted tube  (c) Immobility time in 
the tail suspension test  (d) Immobility time in the forced swim test 
(a) n = KO 18; WT 16   (b) n = KO 19; WT 15   (c)+(d) n = KO 16; WT 16 
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Figure 15: LABORAS data assessed  over 15 h did not show a genotype difference 
Duration of (a) locomotion (b) immobility (c) climbing (d) grooming and (e) eating 




































































































- 58 - 
 Results 
5.5 DOI – Project  
- DOI had different effects on locomotion in Gpm6b null mutants and wildtype mice 
 
5.5.1 Pilot experiment 
The pilot project in wildtype mice performed in order to identify the appropriate dosage 
(“threshold dose”) of DOI revealed no significant difference between the two used dosages of 











5.5.2 Final protocol 
In consequence of the results of the pilot project, it was decided to proceed with a dose of     
0.5 mg/kg DOI. 
The initially assessed baseline of locomotor activity (Fig. 17a) as well as the grooming dura-
tion (Fig. 17c) was the same in Gpm6b null mutants compared to wildtype mice. 
After the injection of 0.5 mg/kg DOI, the locomotor activity (Fig. 17b) during the first 10 min 
of the recording was almost identical between genotypes. However, over the course of the 
following 10 min the locomotor activity of wildtype mice decreased considerably, whereas 
Gpm6b null mutants remained at a higher level. Only during the last third of the trial the   
locomotor activity of Gpm6b null mutants decreased slightly.  


























Figure 16: Pilot project: 
Comparison of different 
doses of DOI in wildtype 
mice 
(a) Locomotor activity 
and (b) grooming behav-
ior at 0.5mg/kg and 0.75 
mg/kg DOI 
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 Results 
The observed patterns of locomotor activity result in a significant interaction effect of time 
and genotype (p = 0.01). 
Compared to baseline level, the grooming duration after injection of DOI (Fig. 17d) increased 
during the first 10 min and decreased in both genotypes during the following 10 min, and then 

















Figure 17: Genotype-dependent effects of DOI on locomotion but not on grooming behavior 
(a) Time mice spent with locomotion without treatment  (b) Time mice spent with locomotion       
following DOI-administration (c) Time mice spent grooming without treatment  (d) Time mice spent 
grooming following DOI-administration 
n = KO 21; WT 17    #p < 0.05 interaction effect of time and genotype 
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5.6 LPS - Project  
- LPS reduced locomotor activity in wildtype mice but not in Gpm6b null mutants 
 
At a dose of 100 µg/kg LPS, neither genotype exhibited reduction in activity 24 h after ad-
ministration. Additionally, the attempt to enhance the depressive-like phenotype with that 
dose failed (data not shown). Therefore, it was decided to increase the dose of LPS to                     
250 µg/kg injected on two consecutive days.  
The baseline of the open field activity (Fig. 18a - 18c) before the injection of 250 µg/kg LPS 
did not show any differences between genotypes (p > 0.05).  
Over the course of 4 days following LPS treatment (Fig. 18d + 18e), velocity and distance 
traveled in the open field revealed a significant effect over time (p = 0.001) and a genotype 
effect that shows a trend towards significance (p = 0.095).  
Posthoc comparisons between activity at baseline level and activity after LPS injection 
showed differences in the effect of LPS treatment between genotypes (for p-values see table 
of Fig. 18f): 24 h as well as 48 h after injection, wildtype mice showed a significant reduction 
in locomotor activity and velocity as compared to baseline level. In contrast, Gpm6b null mu-
tants did not show a decreased activity compared to their baseline level. 96 h after treatment, 
wildtype mice were back to baseline level, whereas Gpm6b null mutants even showed an   
elevated activity compared to baseline.  
The assessment of the body weight over the whole trial revealed that both genotypes exhibited 
a similar curve of temporary weight loss (Fig. 19a). 
The tests for depression performed after the last assessment of the open field activity at 96 h 
post LPS treatment, could support the previously observed genotype effect in the FST (Fig. 
19c) showing that Gpm6b null mutants spent significantly more time immobile (p = 0.048). 
However, the effect was not enhanced by the treatment of LPS compared to the assessment 
with untreated mice (Fig. 14d), nor did Gpm6b null mutants develop a depressive-like       
phenotype in the TST after LPS administration (Fig. 19b; p > 0.05).  
 
 






















Figure 18: In the OFT only wildtype mice develop a reduced activity following LPS treatment 
(a) – (c): Baseline assessments of (a) Total distance traveled (b) Average velocity (c) Time spent in 
different zones (d) Total distance traveled and (e) Average velocity at baseline and different time 
points after LPS injection with baseline equals 100%  (f) Comparisons between baseline level and 
different time points after LPS administration in wildtype mice and Gpm6b knockout mice 













































(a) (b) (c) 
(d) (e) 
(f) 
genotype WT KO WT KO 
baseline vs. 24 h p. inj. 0.0086 0.3605 0.0086 0.3605 
baseline vs. 48 h p. inj. 0.0083 0.6504 0.0083 0.6504 
baseline vs. 96 h p. inj. 0.966 0.0498 0.966 0.0498 
Average velocity Total distance traveled 
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Figure 19: Confirmation of the increased immobility in the FST, but no further differences                 
between genotypes 
(a) Body weight during LPS experiment  (b) Immobility time in the tail suspension test (c) Immobility 
time in the forced swim test  
(a) + (b) n = KO 13; WT 14   (c) n = KO 12; WT 12 




































































































The results of the behavioral testing exhibit distinct differences between Gpm6b null mutants 
and their wildtype littermates. Gpm6b null mutants showed an increased activity in the ele-
vated plus maze, an impaired prepulse inhibition and a greater immobility time in the forced 
swim test. There are hints for an impaired extinction of contextual fear memory. Challenge 
with the serotonin agonist DOI revealed variations in the effect of this drug dependent on the 
genotype – whereas wildtype mice developed a reduced locomotor activity after injection, 
Gpm6b null mutants were less susceptible. Also, the injection of LPS caused a reduction of 
locomotor activity in wildtype mice, but not in Gpm6b null mutants. Altogether, this data 
underscores a depressive-like phenotype in Gpm6b null mutants, associated with altered sero-
tonergic mechanisms. 
 
6.1 Basic functions - Gpm6b null mutants do not have fundamental impairments  
It is important to emphasize that Gpm6b null mutants do not suffer from fundamental        
impairments that could affect the outcome of other tests. Gpm6b null mutants did not show 
disabilities in terms of vision, olfaction, motor function, hearing or pain sensation compared 
to wildtype mice and therefore a bias of the testing results can be excluded.  
 
6.2 Elevated plus maze - Gpm6b null mutants are prone to enhanced agitation 
Even though the results of the EPM might point to a hyperactive phenotype, it is important to 
note that the EPM test is not a typical test for activity, but for anxiety. Therefore, the increase 
in velocity and the elevated number of arm entries cannot simply be interpreted as hyperactiv-
ity. Instead, it is important to compare the results obtained from the EPM to other tests that 
assess differences in the activity level such as the OFT, the holeboard test and the Morris  
water maze test.  
Looking at the velocity that the mice displayed when performing the OFT, it is notable that 
the activity of Gpm6b null mutants also tended to be slightly increased. However, the          
exploratory activity in Gpm6b null mutants when performing the holeboard test and the    
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velocity in the Morris water maze test were unchanged, disproving that just a general           
hyperactive phenotype is present. In fact, the increased activity of Gpm6b null mutants in the 
EPM may be evoked by the environment of the experimental setting. It is likely that the mice 
felt irritated by the novelty and complex structure of the EPM and therefore showed an         
increased agitation. This hypothesis is supported by the fact that the EPM was the first test 
that was performed and the procedure of being tested was still unfamiliar to the mice. The 
observed hyperactivity may be due to the higher likelihood of Gpm6b null mutants to become 
insecure and hence agitated by novel surroundings and is expressed as enhanced activity.  
This phenotype can be transferred to human studies, where patients show a higher prevalence 
of psychomotor and verbal agitation than the healthy control group during depressive        
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6.3 Forced swim test - Gpm6b null mutants exhibit depressive-like features  
Interestingly, Gpm6b null mutants showed a depressive-like phenotype only in the FST, but 
not in any other test that is designed to measure depression specifically. It is especially      
remarkable that the immobility time in the TST did not show any differences, since this test 
also measures the time mice spent in an unpleasant situation without struggling for escape.  
It is preferable to have a model which depressive-like phenotype extents to more than one of 
the tests, but it is not uncommon to find divergent results in the FST compared to other tests 
and it can be assumed that the FST and TST do not measure the same processes. Lira et al. 
(2003) as well as Holmes et al. (2003) found that serotonin transporter knockout mice with a 
129S6/SvEv background had an increased immobility in the FST but a decreased immobility 
in the TST. In contrast, Perona et al. (2008) observed that serotonin transporter knockout mice 
on a C57BL/6J-129Sv mixed background exhibited a reduced immobility in the TST whereas 
the FST did not show any differences between genotypes.  
These findings point to two conclusions: Firstly, as already described in earlier studies, the 
mouse strain seems to play an important role and results are not comparable between strains 
(Bai et al., 2001, Petit-Demouliere et al., 2005). And secondly, the FST and TST cannot be 
considered as interchangeable but must be seen as two individual readouts (Petit-Demouliere 
et al., 2005), although research still needs to investigate the specific differences of these     
paradigms.  
Anhedonia, measured as lowered preference for sucrose, was not observed in Gpm6b null 
mutants, whereas some other studies could link anhedonia to the depressive phenotype of   
certain mouse strains or treatments. For example, chronic mild stress as well as prenatal stress 
could be proven to evoke anhedonia in rodents (Harkin et al., 2002, Willner, 2005, Miyagawa 
et al., 2011) and p11 knockout mice exhibited anhedonia as compared to wildtype mice 
(Svenningsson et al., 2006). 
Taken these studies into account, it can be concluded that mice showing a depressive-like 
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6.4 Prepulse inhibition - Changes in the serotonergic system may lead to an impaired PPI 
Startle, a reaction to a sudden stimulus that can be of tactile, visual or acoustic nature, is    
characterized by a fast twitch of body and facial muscles, an arrest of ongoing behavior and 
an acceleration of the heart beat (Koch, 1999). If the startle stimulus is preceded by a low-
intensity, non-startling prepulse, a reduction of the startle amplitude is observable. This    
phenomenon is referred to as prepulse inhibition (PPI) (Hammond et al., 1972). The startle 
response can be reliably quantified, and by using almost identical stimulus parameters in    
humans and rodents, it is possible to compare the readouts across species (Swerdlow et al., 
1992). 
Impairments in PPI, a test for sensorimotor gating, are thought to reflect the loss of the     
physiologic ability to properly suppress or gate certain irrelevant motor, sensory or cognitive 
information and are associated with diseases such as schizophrenia, obsessive-compulsive     
disorder, Tourette´s syndrome or Huntington disease. The patients may experience the im-
pairment in gating as intrusive thoughts, adventitious movements or sensory information 
(Koch, 1999). According to MacLeod and Mathews (1991), the failure of patients with de-
pression to inhibit intrusive negative thoughts can also be characterized by clinical gating def-
icits. 
Assessing startle response and PPI of Gpm6b null mutants revealed an unaltered startle       
response but a reduction of PPI compared to wildtype mice.  
Reduced PPI is observed under a variety of experimental conditions that influence different 
neurotransmitter systems in animals (Koch, 1999). In particular, manipulations of the dopa-
minergic system (Swerdlow et al., 1994), the noradrenergic system (Sallinen et al., 1998) and 
the glutamatergic system (Mansbach and Geyer, 1989) have been associated with disruptions 
of PPI. Also, numeral studies focussing on the serotonergic system could demonstrate that 
this system is linked to the mechanisms of sensorimotor gating. In a study by Fletcher et al. 
(2001) the tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA) was able to de-
crease PPI without altering basal startle response. In the same study, the authors could show 
that the 5-HT1A receptor agonist 8-OH-DPAT disrupted PPI in rats and this effect was poten-
tiated when the animals were depleted of serotonin. The 5-HT1A receptor functions as an             
autoreceptor: Stimulation of the receptor leads to an inhibition of the activity of raphe seroto-
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nin neurons and a reduced serotonin release (Hjorth and Sharp, 1991). Therefore, it may be 
concluded that the effect of 8-OH-DPAT to decrease PPI could be due to reduced serotonin 
functions (Fletcher et al., 2001). 
In contrast, various drugs have been shown to disrupt PPI in rodents via stimulation of      
serotonin function including the serotonin releasers fenfluramine, p-chloroamphetamine and 
3,4-methylenedioxy-methamphetamine (MDMA) (Kehne et al., 1996).  Manipulation of    
multiple serotonin receptor subtypes can influence PPI. Selective blockage of 5-HT2A recep-
tors (Sipes and Geyer, 1995), non-selective blockage of 5-HT2 receptors as well as deletion of 
5-HT1B receptors (Dulawa et al., 1997) prevented the disruptive effects of receptor agonists 
without altering the PPI itself.  
Considering these observations it can be postulated that both increases and decreases in     
serotonin activity disrupt PPI in rodents and that various receptor subtypes play a role in PPI 
(Fletcher et al., 2001).  
Interestingly, it was shown that certain serotonin uptake inhibitors (such as fluoxetine or   
fluvoxamine) fail to have an effect on PPI in rats (Martinez and Geyer, 1997) or humans 
(Phillips et al., 2000). This observation indicates that an unphysiological function of the     
serotonin transporter may not be the only cause of an impaired PPI, but that also other    
pathways, such as disturbances of the hypothalamic pituitary adrenal (HPA) axis should be      
considered. As already described previously, disturbances of the HPA axis are thought to be a 
main characteristic feature of depression (Palazidou, 2012). Dirks and colleagues were able to 
show that the corticotropin-releasing factor (CRF) may also be involved in alterations of PPI 
in rodents (Dirks et al., 2002). In their study mice overexpressing CRF showed reduced PPI 
compared to wildtype controls. Recently, Conti (2012) could additionally reveal the link be-
tween CRF levels and the serotonergic system. In Wistar-Kyoto rats, neither CRF infusion 
nor the 5-HT1A receptor agonist 8-OH-DPAT alone decreased PPI, but the combination of 
both treatments led to a significant reduction. Similar observations were made when perform-
ing the same experiment with Brown Norway rats (Conti, 2012). These findings are supported 
by the fact that the two CRF receptors (CRF1 and CRF2) are expressed in brain regions 
known to modulate startle response and prepulse inhibition, such as the basolateral amygdala, 
frontal cortex and hippocampus (Swerdlow et al., 2001) and there is a projection from                  
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CRF-containing neurons located in the central nucleus of the amygdala to the major dopamin-
ergic, noradrenergic and serotonergic nuclei (for review see Gray, 1993). 
Not only animal experiments were performed addressing this subject, but also studies with 
depressed human patients were conducted. Ludewig and Ludewig (2003) did not find any 
differences in PPI between depressed patients and healthy controls. In contrast, a study by 
Perry et al. (2004) assessed PPI in patients suffering from depression or schizophrenia and 
compared the results to healthy controls. Depressed patients showed PPI levels that were less 
reduced than the levels of schizophrenic patients, but showed a non-significant tendency to-
wards lower PPI as compared to the control group. The finding by Perry and colleagues is in 
line with the previously described reduced PPI found in Gpm6b null mutants. 
 
 
Figure 20: Comparison of PPI results from healthy controls, patients suffering from schizo-
phrenia or depression (Perry et al. (2004)) 
 
 
The underlying mechanisms leading to PPI are still not fully understood (for review see Koch, 
1999). The PPI circuit for auditory prepulses is assumingly composed of the lower parts of the 
ascending auditory system (including cochlea nuclei, superior olivary complex and nuclei of 
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the lateral lemniscus), the inferior and superior colliculus, and the pedunculopontine tegmen-
tal nucleus (PPTg). 
The attenuating influence of the prepulse is thought to act at the level of the pontine reticular 
nucleus (PnC) by inhibitory cholinergic (muscarinergic) input to the PnC (for review see 
Koch, 1999). 
Ach: Acetylcholine; GABA: γ-aminobutyric acid; Glu: glutamate; 5-HT: serotonin 
Figure 21: Simplified hypothetical circuit of startle response and PPI  
(mod. from Koch (1999)): 
 
 
PPI, as a test of sensorimotor gating, may also be reduced when the involved axons and the 
associated myelin are impaired and M6B has been shown to be associated with the mye-
lination process (Werner et. al., 2001).  
M6B constitutes only 0.05% of the total myelin protein and is therefore much less abundant 
than the most frequently found protein of CNS myelin, the proteolipid protein (PLP) with 
15.43% (Werner et al., 2013). The authors could show that M6B, which shares 57% sequence 
identity with PLP, is associated with the same cholesterol-rich oligodendroglial               
membrane-microdomains. Even though both proteolipids can bind membrane-cholesterol, 
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demonstrated that only PLP is efficiently incorporated into mature myelin and therefore eligi-
ble to contribute to the high cholesterol content of myelin. Mice lacking M6B or PLP were 
fully myelinated and myelin assembly was comparable to wildtype mice, whereas mice lack-
ing PLP and M6B revealed severe impairments including hypomyelination and enhanced neu-
rodegeneration, reflected in motor defects such as ataxia, tremor, and spasticity and resulted 
in premature death at 4-5 months (Werner et al., 2013). 
Analyzing myelination with electron microscopy, it was found that the adaxonal glial mem-
brane in mice lacking only M6B appeared occasionally “fused” with the axonal membrane 
and axons were sometimes double-myelinated and the oligodendroglial plasma were occa-
sionally invaginated into the axon (Werner et al., 2013). 
It has to be further investigated whether the interaction of Gpm6b with the serotonin        
transporter or the involvement of this protein in myelination and hence a possible delay in 
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6.5 Fear conditioning and extinction – Hints for a longer lasting memory of aversive events in 
Gpm6b null mutants 
The results of the contextual fear conditioning test with elevated freezing levels of Gpm6b 
null mutants 48 h after the training indicated a potential impairment of the reduction of aver-
sive memories. It has been shown that patients suffering from depression often have a better 
memory, especially for negative stimuli, compared to neutral or positive ones (Davidson et 
al., 2002), although cognitive dysfunction is a common feature of depression (Thomas and 
O'Brien, 2008). Enhanced fear conditioning or impaired fear extinction are also linked to the    
development of anxiety disorders, which often co-occur with depressive symptoms and both 
conditions exhibit a more severe course when expressed simultaneously (Holtzheimer et al., 
2005).  
Animal studies could support the observations of human samples especially with regard to 
manipulations of the serotonin transporter: Genetic knockout of the serotonin transporter has 
been shown to increase anxiety as well as depressive-like behavior in mice (Zhao et al., 2006, 
Kalueff et al., 2007). Furthermore, Wellmann and colleagues could show that serotonin trans-
porter knockout mice revealed impaired fear extinction and corticolimbic alterations 
(Wellman et al., 2007). In another study conducted by Yu et al. (2011), mice with depressive-
like behavior due to social defeat exhibited an enhanced fear memory when tested 24 h after 
the training session.  
Contextual fear conditioning is mainly a process of hippocampal learning (Tronson et al., 
2012) and an impairment of the cognitive capabilities of the hippocampus may also have an 
effect on the performance in the Morris water maze test as it is used to assess hippocampal 
learning deficits. However, Gpm6b null mutants did not show any differences in the results of 
the Morris water maze as compared to wildtype mice. The study mentioned previously by Yu 
et al. (2011)  observed that the enhanced fear memory of socially defeated mice was not     
associated with impairments in the performance of the Morris water maze. This finding may 
indicate that the two readouts are not necessarily related.  
Fear conditioning is thought to be processed mainly by the hippocampus and the amygdala 
with the hippocampus being attributed to contextual memory, whereas the amygdala is       
associated with the processing of the cue and cued memory. During the extinction process, 
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freezing behavior decreases reflecting new learning about a negative relationship between the 
context and the foot shock (Tronson et al., 2012). The reduction in freezing levels displays the 
learning curve of the mice that a previously threatening stimulus is now regarded as safe 
(Bouton, 2004). During extinction, the infralimbic medial prefrontal cortex (PFC) is involved 
in this circuit by inhibiting the amygdala (Tronson et al., 2012). 
 
                            
         
 
Figure 22: (a) Fear condition circuit (b) Extinction process  
(mod. from Tronson et al. (2012)) 
 
 
PFC: Prefrontal cortex 
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The extinction curve assessed with Gpm6b null mutants and wildtype mice did not mirror the 
results of the previously obtained fear conditioning paradigm. Both genotypes displayed the 
same pattern of fear extinction and further discussion is required to investigate the             
differences: It is possible that the time period between the training session and the first expo-
sure to the same context makes a difference regarding fear extinction. For the initial fear con-
ditioning test, the time interval had been 48 h, whereas the first exposure for the extinction 
protocol was conducted 24 h after training. Interestingly, Gpm6b null mutants displayed a 
similar amount of freezing time independently of the time passed, whereas the wildtype lit-
termates revealed a reduction of freezing behavior when the training-testing interval is great-
er. Therefore, it may be postulated that Gpm6b null mutants have a longer lasting memory of 
the aversive event when not exposed to the same context in the intervening time. 
Unfortunately, all accessible extinction protocols started testing the mice at a 24 h interval 
after the training session and therefore it is not possible to compare the findings. It would be 
interesting to investigate if a new cohort tested initially at 48 h after training can support the 
previous finding and possibly reveal additional alterations in the extinction curve.  
The discrepancies in the results between fear conditioning testing and fear extinction may be 
the history of the different cohorts used influencing the outcome. Even though the mice were 
about the same age when tested (6-7 months), the first cohort had already absolved more   
experiments before performing the fear conditioning test. It should be considered that the pre-
vious testing associated with cognitive challenges as well as stress and other factors has 
caused changes in the brain that subsequently affected fear conditioning and extinction. To 
eliminate this bias in future research, mice should not have been tested in other tests prior to 
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6.6 DOI – Project - DOI effects are dependent on the serotonin levels 
DOI, a potent 5-HT2 agonist, evokes different responses in mice (for review see Canal and 
Morgan, 2012). The head-twitch response (HTR) as a fast retraction of the neck muscles is 
thought to be mainly mediated by activation of 5HT2A receptors, whereas the ear-scratch   
response (ESR) that is described as “rapid scratching movement of the head, neck, or lateral 
area by either hind limb” (Darmani et al., 1996) is assumed to be provoked mainly by 5-HT2C 
receptors (Darmani and Gerdes, 1995). There are several other behavioral responses to sero-
tonergic compounds classified as the “serotonin syndrome” and contain behavioral readouts 
such as flat body posture, forepaw treading, hind limb abduction, lower lip retraction or 
backwards walking (Canal and Morgan, 2012). However, these observations are primarily 
induced by agonists at 5-HT1 receptor subtypes (Tricklebank et al., 1984). 
DOI also has an effect on locomotor activity, although the changes in the activity level do not 
seem to be consistent among species. Several studies could show the inhibitory effect of small 
doses of DOI (e.g. 0.27 mg/kg) in rats on locomotion; an effect that could be antagonized by 
5-HT2A receptor antagonists (Wing et al., 1990). A study with the least shrew could reveal 
that DOI at relatively higher doses (1.25 – 2.5 mg/kg) significantly reduced locomotor activi-
ty (Darmani et al., 1994), whereas the same author observed that similar doses of DOI           
(1 – 2.5 mg/kg) were able to significantly enhance locomotor activity in mice (Darmani et al., 
1996).  
The relatively low dose (0.5 mg/kg) that was used to compare the effects between Gpm6b null 
mutants and wildtype mice led to a significant interaction effect of time and genotype with a 
reduction in locomotor activity that was more pronounced in wildtype mice. This result seems 
to be contrary to the findings of Halberstadt et al. (2009). In the study, the authors describe 
that DOI produced an inverted U-shaped dose-response function in male C57BL/6J mice. 
Lower doses of 0.625 – 5 mg/kg DOI increased the locomotor activity in these mice and only 
doses higher than 10 mg/kg caused a reduction in locomotion (Halberstadt et al., 2009). 
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Figure 23: Effects of DOI on locomotor activity (a) Dose response of DOI effects on distance traveled 
(in cm). Mice used were male C57BL/6J. Data are mean ±SEM. *p < 0.05, Dunnett’s test vs. vehicle 
control. (b) The effects of high doses of DOI on locomotor activity were evaluated in a second dose-
response experiment. Data shown are distance traveled (cm) during the first 10 min of testing. Data are 
mean ±SEM. *p < 0.05, Dunnett’s test vs. vehicle control (Figures from Halberstadt et al. (2009))  
 
Halberstadt et al. (2009) could additionally demonstrate that the enhancement of locomotor 
activity provoked by a dose of 1 mg/kg DOI was absent in 5-HT2A receptor knockout mice 
and that the reduction of activity induced by 10 mg/kg was potentiated in 5-HT2A knockout 
mice and attenuated when the mice were pretreated with the selective 5-HT2C/2B antagonist 
SER-082. This finding indicates that the 5-HT2A and 5-HT2C receptors provoke opposing  
effects with 5-HT2A receptors (assumed to be primarily targeted by lower doses of DOI)   
leading to an increase in locomotor activity and 5-HT2C receptors (assumed to be primarily 
targeted by higher doses of DOI) leading to a reduction of locomotor activity (Halberstadt et 
al., 2009). The authors could support this result by proving that the selective 5-HT2C receptor 
agonist WAY 161.503 reduces locomotion levels in these mice and that this effect is potenti-
ated in 5-HT2A knockout mice (Halberstadt et al., 2009).  
Unfortunately Halberstadt and colleagues did not mention the exact age of the tested mice in 
their publication. This would have been important information since it has been assumed that 
the effects of DOI are also age dependent.  
Another study tested male and female ICR mice across a wide age range investigating the 
effects of DOI on HTR, ESR and locomotor activity (Darmani et al., 1996). The authors could 
show that DOI (1 mg/kg and 2.5 mg/kg) was able to increase the locomotor activity compared 
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to vehicle control mice with the maximal locomotor activity seen between the age of 28-35 
days. Following that peak, the locomotor activity subsided in a pattern that was similar to the 
one observed in vehicle control mice (Darmani et al., 1996). The age of onset of HTR as well 
as ESR occurred about 2-3 weeks postpartum with maximal HTR on 28 days of age and max-
imal ESR frequency between the age of 22-35 days. Following that peak the number of HTR 
tended to decrease with increasing age without reaching significance, whereas ESR frequency 
decreased significantly till day 180 where no difference to vehicle control animals was ob-
servable anymore (Darmani et al., 1996). 
Interestingly, it has been shown that 5-HT2A receptor density levels decrease with increasing 
age in both rodents and humans (for review see Canal and Morgan, 2012). This finding could 
explain the reduction of locomotor activity in the mice described in this thesis (which were 
about 7 months old at the time of testing), whereas most other authors   describe an increase 
of locomotor activity at similar low doses. One possible explanation for the discrepancy could 
be that the reduction of 5-HT2A receptors in older mice causes DOI to evoke mainly 5-HT2C 
related effects and therefore a reduction of locomotion levels even though relative low doses 
(such as the used dose of 0.5 mg/kg) are generally associated with an increased locomotor 
activity (e.g. Darmani et al., 1996, Halberstadt et al., 2009). This explanation is supported by 
the study from Halberstadt et al. (2009), in which the locomotor-decreasing effect of 10 
mg/kg DOI is potentiated in 5-HT2A knockout mice, indicating that this receptor serves to 
mask the locomotor-reducing effects that the 5-HT2C receptor mediates when targeted by high 
doses of DOI. 
No differences were found in grooming activity, which is consistent with the finding from 
Darmani et al. (1996) that ESR was completely absent at the age of 180 days and in general a 
dose of at least 1 mg/kg DOI was needed to induce robust ESR (Darmani and Gerdes, 1995). 
Based on video recordings, it was not possible to reliably rate HTR neither in Gpm6b null 
mutants nor in wildtype mice after injection of 0.5 mg/kg DOI. This may be due to insuffi-
cient screen resolution that lacks details which are necessary to detect HTR or to the lack of 
experience of the observer. However, it is more likely that the mice did not exhibit any HTR. 
As mentioned earlier, HTR are mediated by 5-HT2A receptors (Darmani et al., 1996) and    
taking into account that with increasing age the number of this particular receptor is reduced, 
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it can be assumed that DOI failed to provoke HTR due to a lack of mediating receptors.     
Additionally, the dose of 0.5 mg/kg is quite low compared to the dose used by other authors.  
Darmani et al. (1996) tested mice that were injected with a dose of 1 mg/kg respectively      
2.5 mg/kg DOI. Canal et al. (2010) observed a maximal HTR in 8-week-old mice when     
injected with 0.8 mg/kg DOI and Weiss et al. (2003) described substantial but submaximal 
HTR in 3-months-old-mice at dosages of 0.75-1 mg/kg.  
For testing Gpm6b null mutants, a relatively low dose was used with the intention to find a 
threshold dose of DOI that has an effect on wildtype mice but not on Gpm6b null mutants. 
This difference was successfully proven by the interaction effect in terms of the locomotor 
activity. Gpm6b null mutants were less susceptible to the reducing effects of DOI on locomo-
tor activity compared to wildtype mice. This finding is in line with the postulation that 
Gpm6b null mutants may have a lack of serotonin in the synaptic cleft and therefore more 
DOI is tolerated before behavioral effects are observable.  
It is possible that alterations of the behavioral pattern in Gpm6b null mutants after DOI injec-
tion are not due to the serotonin levels directly but to adaptations of the serotonergic system, 
e.g. changes in the receptor density. It has not been investigated yet if Gpm6b null mutants 
have alterations regarding the receptor numbers. According to Fox et al. (2007), serotonin 
transporter knockout mice that also serve as a model of depression due to altered serotonin 
levels (Zhao et al., 2006, Kalueff et al., 2007, Wellman et al., 2007), exhibit only modest 
changes in 5-HT2A and 5-HT2C binding sites, whereas another study with serotonin transporter 
knockout mice revealed alterations of density of both receptor subtypes in a brain region-
specific manner (Li et al., 2003). 
In summary, Gpm6b null mutants exhibit a different reaction to DOI administration compared 
to wildtype littermates. It can be postulated that a higher dose of DOI may have been able to 
provoke HTR, but this gain would be potentially associated with a loss of the readout for   
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6.7 LPS – Project – Gpm6b null mutants did not develop a reduced locomotor activity 
 
When assessing the effects of LPS on mouse behavior, it is mandatory to distinguish between 
the terms sickness behavior and depressive-like behavior.  
Lipopolysaccharide (LPS) presents a typical molecular pattern that is eligible to provoke 
sickness behavior due to a systemic inflammation in the body. LPS is a fragment of gram 
negative bacteria and binds to toll-like receptor-4 on monocytes and macrophages which acti-
vates a complex intracellular signalling cascade (Dantzer, 2004). Systemic administration of 
LPS induces the expression of pro-inflammatory cytokine mRNAs and proteins in the brain 
and leads to typical behavioral changes associated with sickness such as social withdrawal, 
reduced motor activity, altered cognition, decreased food and water intake as well as a 
hunched posture (Dantzer et al., 2008).  
The severity of the effects caused by LPS is highly associated with the age of the animals. It 
could be demonstrated that the lethal dose (LD) where 50% of the 6-7 weeks old mice died 
equalled 25.6 mg/kg, whereas the LD50 for mice that ranged from 98-102 weeks of age was 
only 1.6 mg/kg (Tateda et al., 1996).  
Depressive-like behavior is thought to occur subsequently to sickness behavior, but since  
depressive-like behavior shares several features with sickness behavior, such as anorexia, 
cognitive changes, and mood changes, it can be a confounding factor (Moreau et al., 2008). It 
cannot be generalized at which time point sickness ends and depression starts. This is mainly 
due to the different protocols, strains, and age ranges various authors used, which make the 
results barely comparable. For example, Frenois et al. (2007) postulates that sickness behavior 
after a single i.p. injection of 830 µg/kg LPS in 8 week old mice is already negligible at 24 h 
post injection, whereas Godbout et al. (2008) found that at a dose of 330 µg/kg that was in-
jected to 3-6 months old mice provoked sickness behavior that lasted up to 48 h. Various 
studies measured the immobility time in the FST or TST shortly after LPS-injection and 
therefore assumingly assessed the sickness behavior rather than the depressive-like behavior 
as claimed (e.g. Dunn and Swiergiel, 2005, de Paiva et al., 2010). 
The pathways through which LPS is thought to evoke depressive-like behavior have already 
been discussed in the introductory section. In summary, the increased release of cytokines is 
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assumed to activate the enzyme IDO which causes a degradation of tryptophan down the 
kynurenine pathway instead of synthesizing serotonin (Dantzer et al., 2008). Additionally, 
cytokines alter the negative feedback mechanism of cortisol (Zunszain et al., 2012), which 
leads to elevated plasma levels of cortisol and ACTH and cytokines are able to activate the 
serotonin transporter over MAPK p38 (Zhu et al., 2010).  
At a dose of 250 µg/kg injected on two consecutive days, sickness behavior was observable 
shortly after injection as hunched posture and extremely reduced locomotion.  
In order to evaluate if sickness behavior, measured as reduced locomotor activity, is still pre-
sent at various time points after LPS injection, mice were tested in the open field test at 24 h, 
48 h and 96 h after treatment. This way it was hoped to circumvent the bias of confounding 
sickness – and depressive-like behavior. With this higher dosage, wildtype mice showed re-
duced motor activity when tested in the open field 24 h and 48 h after the second injection and 
the activity level was back to baseline at 96 h post injection. In contrast, Gpm6b null mutants 
did not reveal a reduced locomotor activity in either of the trials. This leads to the thought that 
Gpm6b null mutants have a mechanism that prevents them from exhibiting a decreased     
activity.  
One hypothesis for this finding is that reduced serotonin levels are the determining factor. In 
both genotypes the induction of inflammatory processes possibly caused a reduction of extra-
cellular serotonin. The remaining serotonin could bind on 5-HT2C receptors and lead to a   
decrease in the activity level similar to the observations made after the injection of the seroto-
nin receptor agonist DOI. Hypothetically, wildtype mice had still more serotonin available 
compared to Gpm6b null mutants and therefore the effects of the LPS injection were more 
pronounced in wildtype mice. In contrast, Gpm6b null mutants did not show a significant re-
duction of locomotor activity.  
The reduction of the body weight displayed a very similar curve in the genotypes suggesting 
that the LPS indeed affected both genotypes in a similar manner and that the differences are 
restricted to locomotor activity.  
Another possible explanation (purely hypothetical at this point) is that different corticosterone 
levels contribute to the altered behavioral readouts of Gpm6b null mutants and wildtype mice. 
Taking the cytokine hypothesis of depression into consideration it may be postulated that 
- 80 - 
 Discussion 
Gpm6b null mutants have increased levels of corticosterone (which functions are comparable 
to human cortisol) that are multiplied by LPS injection, whereas wildtype mice do not have 
increased basal corticosterone levels. It is known that glucocorticoids are potent inhibitors of 
many inflammation-associated processes and thought to upregulate anti-inflammatory media-
tors (van der Velden, 1998). Consequently, the inflammatory response to LPS injection is less 
distinct in Gpm6b null mutants than in wildtype mice due to the inflammatory suppressing 
effects of elevated corticosterone levels.  But postulating this, Gpm6b null mutants could be 
expected to have a less severe loss of body weight compared to wildtype mice, which was not 
observable in this study. 
Gpm6b null mutants revealed an increased activity in the open field test 96 h after LPS      
injection compared to baseline assessment. An increased activity in the open field test after 
injection of LPS could also be demonstrated by Zhu et al. (2010). At a dose of 200 µg/kg 
LPS, mice showed an increased activity in the open field test 24 h after injection compared to    
saline-injected mice. Why the activity level increases at that time point must be studied. It is 
possible that over-compensatory mechanisms cause that appearance, but the exact pathways 
still have to be investigated. 
In summary, the pharmacological challenge with LPS did not provoke an enhancement of the 
depressive-like phenotype in Gpm6b null mutants, but LPS had different effects depending on 
the genotype. 
- 81 - 
 Conclusion and perspective 
 
7 Conclusion and perspective 
 
Testing of Gpm6b null mutants provided valuable new insights into this mouse strain and its 
relation to the serotonergic system, with the possibility to use the strain as a mouse model of 
depression. Behavioral differences in Gpm6b null mutants compared to their wildtype       
littermates were found in the elevated plus maze, prepulse inhibition, fear conditioning, and 
forced swim test. The responses to DOI and LPS differed between genotypes supporting an 
involvement of serotonergic pathways. The majority of the conducted tests did not reveal dif-
ferences in the behavior, which makes the results of significant outcomes even more distinct 
as confounding factors are negligible. 
By testing a large number of animals in various tests it was possible to characterize this 
mouse strain in a very comprehensive manner and demonstrate its qualification to serve as a 
mouse model of depression. However, research should not cease at this point, but further pur-
sue that path and extent the knowledge about this interesting mouse strain.  
Pharmacological validity of this model should be evaluated by investigating whether the     
depressive-like phenotype of Gpm6b null mutants is reversible by administration of serotonin 
re-uptake inhibitors. Furthermore, data from female Gpm6b null mutants should be obtained 
and compared to the tested males. Another interesting approach would be to investigate 
whether it is possible to enhance the depressive-like phenotype of these mice by using        
paradigms such as learned helplessness, chronic stress or maternal deprivation models. 
Additional molecular studies should be conducted in order to investigate the amount of     
serotonin in the synaptic cleft, serotonin transporter density, and detect potential alterations of 
serotonin receptors. Finally, human data should be added to the behavioral results of these 
mice to support the association of the glycoprotein M6B with depression in human patients. 
 
 




Caroline Ritter:  Comprehensive behavioral characterization of Gpm6b null mutants as a  
     mouse model of depression 
 
In this thesis male Gpm6b null mutants on a C57BL/6J background were characterized in    
various behavioral test settings. Gpm6b null mutants, as yet an entirely uncharacterized 
mouse strain, are lacking the glycoprotein M6B that inhibits the serotonin transporter surface 
expression. Knockout of the Gpm6b gene may lead to a depressive-like phenotype in these 
mice due to a surface overexpression of serotonin transporters and hence a more efficient 
clearing of serotonin from the synaptic cleft.  
The performed tests could show distinct changes in the behavior of Gpm6b null mutants   
making this strain a promising mouse model of depression: Gpm6b null mutants demonstrated 
an increased velocity in the elevated plus maze test interpreted as mild hyperactivity similar to 
agitation seen in human patients suffering from depression. Gpm6b null mutants revealed an 
increase in immobility time in the forced swim test - a test that is typically used to assess   
depressive-like behavior in rodents. Hints for reduced contextual fear extinction were observ-
able in these mice suggesting an impaired extinction of aversive memories. Additionally, an 
impaired PPI would be in line with the involvement of the serotonergic system. 
The i.p.-injection of the 5-HT2A/2C receptor agonist (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-
aminopropane hydrochloride (DOI) at a dose of 0.5 mg/kg demonstrated the divergent effects 
of the drug depending on the genotype: Whereas the administration of DOI caused a reduction 
of locomotor activity in wildtype mice after a short delay, Gpm6b null mutants were less   
susceptible, consistent with less serotonin in the synaptic cleft. Furthermore, the injection of 
the pro-inflammatory substance lipopolysaccharide (250 µg/kg on two consecutive days, i.p) 
to wildtype mice and Gpm6b null mutants revealed that Gpm6b null mutants did not exhibit 
the temporarily reduced locomotor activity found in wildtype mice.  
To conclude, behavioral tests revealed a mild depressive-like phenotype in Gpm6b null     
mutants. Pharmacological challenges (DOI, LPS) support an involvement of the serotonergic 
system in the observed phenotype. 




Caroline Ritter:  Umfangreiche Verhaltenscharakterisierung von Gpm6b-Nullmutanten  
     als Mausmodell für Depression 
 
Im Rahmen der Dissertation wurden männliche Gpm6b-Nullmutanten vom Typ C57BL/6J in 
zahlreichen Verhaltenstests charakterisiert. Bei den beschriebenen Tieren handelt es sich um 
eine genetisch entwickelte Mauslinie, der das Glykoprotein M6B (Gpm6b) fehlt. M6B 
reduziert unter physiologischen Bedingungen die Oberflächenexpression des 
Serotonintransporters. Hypothetisch kommt es somit bei Gpm6b-Nullmutanten zu einer 
Überexprimierung des Serotonintransporters und daher zu einer effizienteren 
Wiederaufnahme von Serotonin aus dem synaptischen Spalt. Es wird postuliert, dass knockout 
des Gpm6b-Genes auf diese Weise zu der Ausprägung eines depressions-ähnlichen Phänotyps 
der Mäuse führt.  
Bei den durchgeführten Tests konnten deutliche Unterschiede im Verhalten der Gpm6b-
Nullmutanten im Vergleich zu Wildtyp-Mäusen nachgewiesen werden, was diese Mauslinie 
zu einem vielversprechenen Model für Depression macht. 
Gpm6b-Nullmutanten zeigten eine erhöhte Aktivität im elevated plus maze, welche als ein 
Zustand der Agitation interpretiert werden kann, wie dieser auch teilweise bei depressiven 
Patienten beobachtet wird. Zusätzlich zeigten Gpm6b-Nullmutanten eine erhöhte 
Immobilitätszeit im forced swim test – einem Test, welcher üblicherweise genutzt wird um 
depressions-ähnliches Verhalten bei Mäusen und Ratten zu beurteilen. Im fear conditioning 
test konnten Hinweise auf eine reduzierte Extinktion aversiver Erlebnisse aufgezeigt werden 
und die beobachtete gestörte prepulse-Inhibition der Gpm6b-Nullmutanten spricht für eine 
Beteiligung des serotonergen Systems. 
Um die zu Grunde liegenden Abweichungen im serotonergen System zu bestätigen, wurde 
den Mäusen der 5-HT2A/2C Rezeptoragonist (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-
aminopropane hydrochloride (DOI) intraperitoneal (i.p.) in einer Dosis von 0.5 mg/kg 
injiziert. Dies führte bei den Wildtyp-Mäusen zu einer deutlichen Abnahme der Lokomotion 
nach einer kurzen Latenzzeit, während die Gpm6b-Nullmutanten weniger ausgeprägt 
reagierten, übereinstimmend mit einem reduzierten Serotoningehalt im synaptischen Spalt.  
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 Zusammenfassung 
Auch die i.p.-Injektion der pro-inflammatorischen Substanz Lipopolysaccharid (LPS), 
injiziert in einer Dosis von 250 µg/kg an zwei aufeinander folgenden Tagen, führte bei den 
Gpm6b-Nullmutanten nicht zu einer zeitweise reduzierten Aktivität wie sie bei den Wildtyp-
Mäusen beobachtet werden konnte. 
Zusammenfassend lässt sich festhalten, dass die durchgeführten Verhaltenstests einen milden 
depressiven Phänotyp der Gpm6b-Nullmutanten aufzeigen konnten. Pharmakologische 
Herausforderungen (DOI, LPS) unterstützen eine Beteiligung des serotonergen Systems an 
dem beobachteten Phänotyp. 
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12 Appendix 
12.1 List of abbreviations 
 
%     Percentage 
5-HT    5-hydroxytryptamine = serotonin 
5-HTTLPR    Serotonin transporter gene linked polymorphic region 
Ach     Acetylcholine 
ACTH    Adrenocorticotropic hormone 
ANOVA   Analysis of variance 
bp   Base pair 
CNS     Central nervous system 
CRH     Corticotropin-releasing hormone 
dB     Decibel 
DOI     (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane 
DSM-IV-TR   Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition,    
textrevision 
E. coli    Escherichia coli 
et al.   Et alii 
EPM      Elevated plus maze 
ESR     Ear-scratch response  
Fig.   Figure 
FST     Forced swim test 
g    Gram 
GABA   γ-aminobutyrid acid 
Glu     Glutamate  
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Gpm6b    Glycoprotein M6B  
h     Hour; hours 
HEK-MSR-293 Human embryonic kidney-293 
HPA axis    Hypothalamo-pituitary-adrenal axis 
HTR    Head-twitch response  
ICSS   Intracranial self-stimulation  
IDO     Indoleamine 2,3 – dioxygenase  
i.e.    Id est 
i.p.   Intraperitoneal; intraperitoneally 
IFN-α    Interferon-alpha 
IL-1ß     Interleukin-1-beta  
IL-6    Interleukin-6  
KAT    Kynurenine aminotransferase 
kHz    Kilohertz 
kg    Kilogram 
KMO    Kynurenine 3–monooxygenase 
KO  Knockout mice 
KYNA    Kynurenic acid  
KYNU    Kynureninase 
LPS    Lipopolysaccharide  
m    Meter 
mA    Millampere 
MAPK p 38    Mitogen activated proteinkinase p 38 
MDMA    3,4-methylenedioxy-methamphetamine  
min     Minute; minutes 
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ml    Milliliter 
mod.  Modified 
mm    Millimeter 
ms    Millisecond; milliseconds 
NMDA  N-methyl-D-aspartate 
OFT    Open field test 
pcDNA3   Mammalian expression vector 
PCR   Polymerase chain reaction 
PET    Positron emission tomography  
PFC    Prefrontal cortex  
PLP    Proteolipid protein  
PnC    Pontine reticular nucleus  
PPI    Prepulse inhibiton 
PPTg    Pedunculopontine tegmental nucleus  
QUIN      Quinolinic acid  
sec    Second; seconds 
SERT    Serotonin transporter 
SSRIs    Selective serotonin re-uptake inhibitors  
TNF-α     Tumor necrosis factor-alpha 
TPH    Tryptophan hydroxylase 
TST    Tail suspension test 
µg   Mikrogram 
µl    Mikroliter 
vs.  Versus 
WT  Wildtype mice 
